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7ABBREVIATIONS 
AF   Atrial fibrillation 
AMI   Acute myocardial infarction 
AV   Atrioventricular 
BRS   Baroreflex sensitivity 
Ca2+   Calcium ion 
CABG  Coronary artery bypass grafting 
EAD  Early afterdepolarization 
EF   Left ventricular ejection fraction 
HRV  Heart rate variability 
K+   Potassium ion 
MAP  Monophasic action potential 
MAPD  Monophasic action potential duration 
MAPD50  Monophasic action potential duration at 50 % repolarization  
MAPD90  Monophasic action potential duration at 90 % repolarization 
MAPD50600  Monophasic action potential duration at 50 % repolarization during atrial 
pacing at a cycle length of 600 ms 
MAPD90600  Monophasic action potential duration at 90 % repolarization during atrial 
pacing at a cycle length of 600 ms 
Mg2+   Magnesium ion 
MgSO4 Magnesium sulphate
Na2+   Sodium ion 
NYHA  New York Heart Association functional class
SVT   Supraventricular tachycardia 
TdP   Torsade de pointes 
VCG  Vectorcardiography 
VERP  Ventricular effective refractory period 
VPB   Ventricular premature beat 
VF   Ventricular fibrillation 
VT   Ventricular tachycardia 
8LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original publications, which will be referred to in the text by 
their Roman numerals. 
I  Parikka H, Toivonen L, Pellinen T, Verkkala K, Järvinen A, Nieminen MS. The influence of 
intravenous magnesium sulphate on the occurrence of atrial fibrillation after coronary artery by-
pass operation. Eur Heart J 1993; 14; 251-258.  
II  Parikka H, Toivonen L, Verkkala K, Järvinen A, Nieminen MS. Ventricular arrhythmia 
suppression by magnesium treatment after coronary artery bypass surgery. Int J Angiology 1999; 
8; 165-170.
III  Parikka HJ, Toivonen LK. Acute effects of intravenous magnesium on ventricular 
refractoriness and monophasic action potential duration in humans. Scan Cardiovasc J 1999; 33: 
300-305.
IV  Parikka H, Toivonen L, Naukkarinen V, Tierala I, Pohjola-Sintonen S, Heikkilä J, Nieminen 
MS. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute 
myocardial infarction. Eur Heart J 1999; 20: 111-120. 
V  Parikka H, Nieminen MS, Näveri H, Härkönen M. Interrelationship between intracellular 
magnesium and potassium in patients with cardiac arrhythmias. (submitted). 
91.  ABSTRACT 
These clinical investigations were performed to study the effects of intravenously administered 
magnesium sulphate (MgSO4) on the mechanisms causing cardiac arrhythmia propensity. The 
postoperative period following coronary artery bypass grafting (CABG) and the early phase of 
acute myocardial infarction (AMI) were pathophysiological states of arrhythmia generation. 
Hypomagnesemia was hypothesized to have a pathogenetic significance in postoperative 
arrhythmicity. Autonomic regulation of the heart, inhomogeneity in repolarization, ischemia, and 
the magnitude of myocardial injury represent targets of magnesium (Mg2+) action in AMI. The 
occurrence of supraventricular and ventricular arrhythmias stood for arrhythmia manifestations after 
CABG and AMI. The susceptibility to arrhythmias was assessed by two experiments: 1. direct 
effects on cardiac ventricular electrophysiology, and 2. intracellular changes in Mg2+ and potassium 
(K+) concentrations following Mg2+ administration. Subjects with healthy hearts and patients with 
underlying cardiac morbidity and hospitalizion for the treatment of severe cardiac arrhythmias 
comprised the sample for the latter study arm. 
A total of 140 patients undergoing CABG were randomly given 70 mmol of MgSO4 or placebo 
within the two first postoperative days. A clear fall in the serum Mg2+ concentration accompanied 
CABG in patients not given active treatment, but frank hypomagnesemia occurred very seldom. 
The intervention had no effect on the overall appearance or recurrence of atrial fibrillation (AF) (29 
% versus 26 % in magnesium and control patients, respectively). Hypomagnesemia or a low serum 
level of Mg2+ did not predispose to AF, but on the contrary, Mg2+ concentrations were higher in 
patients developing AF. In patients on magnesium treatment, the incidence of AF increased 
significantly from the lowest to the highest quartile of serum Mg2+ concentration on the first day 
(from 11 to 47 %). It turned out that the mean sinus rates were slower in patients with AF 
parallelling the elevation of serum Mg2+. By multivariate modelling, both an elevated serum Mg2+ 
concentration and a slow sinus rate independently and exclusively predicted the appearance of AF.  
Magnesium infusion decreased the incidences of premature ventricular beats (PVBs) and 
complex ventricular arrhythmias early after CABG. In addition to a decreased serum Mg2+
concentration, the number of bypassed vessels, preoperative New York Heart Association (NYHA) 
functional class and preoperative diuretic use independently identified individuals prone to 
postoperative high-risk ventricular arrhythmias. 
Infusion of 70 mmol of MgSO4 within the first 24 h of AMI resulted in a reduction of the 
occurrence of all subsets of early ventricular arrhythmias. No effect was noticed on supraventricular 
arrhythmias. The intervention improved the homogeneity of repolarization both acutely and 
subacutely, as demonstrated by decreased QT dispersion throughout the study period. It did not 
essentially change the autonomic balance, prevalence of ischemia, or size of the evolving 
myocardial injury. Posttreatment serum Mg2+ concentrations correlated inversely and QT dispersion 
at 24 h directly with the appearance of early ventricular arrhythmias. Furthermore, there was a 
strong inverse relation between QT dispersion at 24 h and serum Mg2+ concentration after the 
infusion.
A rapid magnesium infusion of 12 mmol of MgSO4 caused a slight but significant shortening of 
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the monophasic action potential (MAP) duration measured at 50 % and 90 % repolarization. The 
response was seen during spontaneous rhythm and at fixed heart rate. Shortenings of the ventricular 
effective refractory period (VERP) and sinus cycle length were also noted. While the changes in 
cycle length and MAP duration were correlated during spontaneous rhytm, the changes in paced 
MAP duration and VERP were independent of heart rate alterations. 
There was a tendency toward an increase in the intracellular levels of both Mg2+ and K+
following administration of 30 mmol of MgSO4. Serum and intracellular concentrations of Mg2+ or 
K+ did not correlate between each other. A close relationship between the intracellular levels and 
changes (post-infusion values minus baseline values) of Mg2+ and K+ was detected. Specifically, 
when the baseline Mg2+ concentration was plotted against the change in K+, a significant inverse 
relation was found in muscle tissue. The phenomenon may be dependent on low left ventricular 
ejection fraction (EF), but not on diuretic use or severity of arrhythmia. 
With respect to the main hypotheses, the following conclusions may be drawn: The 
postoperative fall in the serum Mg2+ concentration does not cause AF, but it may be associated with 
the generation of ventricular arrhythmias. Correction of the hypomagnesemia suppresses ventricular 
arrhythmicity but the occurrence of AF remains unaffected. During the early hours of AMI, 
pharmacologic Mg2+ doses reduce the occurrence of ventricular arrhythmias, possibly through 
stabilization of the ischemic ventricular repolarization. Furthermore, pharmacologic doses may 
shorten ventricular MAP duration and refractoriness if administered rapidly. Finally, there was a 
dynamic coupling between the intracellular handling of Mg2+ and K+.
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2. INTRODUCTION 
Magnesium is a divalent cation with the ability to form a chelate, a complex of a metal ion and an 
organic compound, which gives it a central role in biological and physiological processes. 
Chlorophyll, the engine of photosynthesis in plants, contains Mg2+ as its core element (Harper 
1973). In mammalian cells including cardiomyocytes, Mg2+ is a cofactor in two main functions: 
enzymatic reactions involving energy production and utilization, and transmembrane electrical 
balance. In these roles, calcium (Ca2+) and K+ ions are inseparable co-actors with Mg2+ (White and 
Hartzell 1989). 
Following the advance in our understanding of the importance of Mg2+ in the cardiac cell 
metabolism it soon became evident that numerous cardiovascular disorders are accompanied by 
hypomagnesemia or magnesium deficiency. Of these, AMI, cardiac arrhythmias, sudden death, 
congestive heart failure, and cardiac surgery are the most frequently quoted (Arsenian 1993). 
Whether magnesium deficiency truly is a pathogenetic operator or a consequence, or even only a 
bystander in relation to the underlying morbidity has not been established. 
Since the first half of the 20th century magnesium salts have been used as an empiric treatment 
for various cardiac arrhythmias, which in those days were mostly due to digitalis toxicity and 
ischemic heart disease (Zwillinger 1935, Boyd and Scherf 1943, Harris et al. 1953). Yet, only 
during the last two decades pertinent controlled clinical studies on the efficacy of magnesium 
treatment in a multitude of arrhythmic events have been conducted. Despite promising clinical 
results and vigorous in vitro and in vivo experiments the antiarrhythmic mechanisms have remained 
elusive. Given the impact of Mg2+ in cardiac myocyte homeostasis, an antiarrhythmic effect might, 
however, be anticipated. The resting transmembrane potential and the normal and abnormal cardiac 
action potential are modified by the action of Mg2+. The membrane bound Na+-K+ pump 
obligatorily needs Mg2+ for its proper function. Cytosolic Mg2+ operates as a regulator of certain K+
channels (Agus and Morad 1991). The magnesium ion possesses Ca2+ channel blocking activity and 
a strong potential to attenuate early afterdepolarizations (EAD) leading to a normalization of 
disturbed repolarization (Iseri and French 1984, Bailie et al. 1988). The principal hypotheses 
underlining the mode of action of intravenously administered magnesium are related to repletion of 
magnesium deficiency, a direct pharmacologic antiarrhythmic effect, and a secondary 
antiarrhythmic effect, such as ischemia relief, unloading of the myocardium by hemodynamic 
alterations, and changes in autonomic nervous control of the heart. 
The present series of investigations aimed at elucidating the effects of intravenously 
administered magnesium on the occurrence, generation, and mechanisms of cardiac arrhythmias. 
The early phases of CABG and AMI represented archetypes of arrhythmicity associated with 
lowered serum Mg2+ levels. Effects on the electrical properties of ventricular myocardium and 
changes in intracellular concentrations were tested as surrogates for propensity to arrhythmias. 
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3. REVIEW OF THE LITERATURE 
3.1. Biophysiology of magnesium 
3.1.1.General 
Magnesium is the second most abundant intracellular and the fourth most abundant of the total 
cation content in the human body. The whole Mg2+ content in the human body is in the range of 21 
- 24 g in an average adult person (Harper 1973, Rude 1989). Mg2+ is clustered in tissues where 
metabolic activity is high, such as the brain, heart, liver and kidney. About 60 % of the body Mg2+
is found in the bone, a third of which is exchangeable, forming a reservoir for the maintenance of 
the normal serum Mg2+ concentration. Approximately 35 % is in the skeletal and heart muscle, and 
1 % in the extracellular fluid compartment. Of the blood Mg2+, 35 % is nonspecifically bound to 
albumin, the rest resides in the ionized form (Rude 1989, Reinhart 1988). 
In an average western diet, 200 - 350 mg of Mg2+ enters the body via the gastrointestinal tract 
daily. Studies with 28Mg2+ have shown that absorption of Mg2+ takes place in the small intestine, 
most efficiently in the chloride form and in an alkaline environment. The absorption mechanism is 
not clear. There is passive transport across the mucosa, and no active system has conclusively been 
identified. The supply of dietary Mg2+ defines the rate of absorption: the smaller the load, the 
greater the amount absorbed. Thus, the proportion of absorbable magnesium can vary between 24 % 
and 76 % of the magnesium load ingested (Harper 1973, Reinhart 1988, Rude 1989). 
Renal tubular reabsorption of Mg2+ accounts for the regulation of the body Mg2+ balance. Mg2+
is filtered by the glomeruli and reabsorbed in the tubules, 60 % - 75 % in the ascending limb of 
Henle, and the rest in the proximal tubule. Reabsorption depends on sodium (Na+) reabsorption and 
tubular flow. With normal renal function, the renal threshold and the renal maximal tubular 
reabsorptive capacity of Mg2+ define the points where it is either totally reabsorbed or completely 
excreted. A specific secretion mechanism for Mg2+ has not been detected and, thus, the relationship 
between the ultrafilterable serum Mg2+ concentration and the renal Mg2+ excretion is linear (Rude 
1989).
Although a specific hormonal control system for the Mg2+ homeostasis has not been established, 
several hormones can influence the flux of Mg2+. Vitamin D and 1,25-dihydroxy-vitamin D3
increase the intestinal absorption of Mg2+. Mild hypomagnesemia may enhance parathyroid 
hormone production, whereas parathyroid hormone itself can increase the tubular reabsorption. A 
reduced level of calcitriol (1,25-dihydroxyvitamin D3) is also associated with hypomagnesemia and 
this is probably due to impaired 1-alpha hydroxylation of vitamin D. Aldosterone, calcitonin, 
antidiuretic hormone, and insulin can affect the renal handling of Mg2+ (Rude 1989). 
Catecholamines can reduce the serum concentration of Mg2+ without enhancing its excretion 
(Ryzen et al. 1990). Hypomagnesemia is often associated with hypocalcemia, which is partly 
independent of parathyroid hormone action, and with hypokalemia, through impaired Na+-K+ pump 
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activity (Harper 1973, Reinhart 1988, Rude 1989). 
3.1.2. Physiological role of magnesium 
All enzymatic reactions that use adenosine triphosphate need Mg2+. Mg2+ acts as a cofactor in 
enzyme-substrate reactions involving transfer of phosphate groups, such as kinases (hexokinase, 
creatine kinase, protein kinase, phosphofructokinase), Na+-K+-ATPase, Ca2+ -ATPase, GTPase and 
cyclases (adenylate cyclase, guanylate cyclase). The magnesium ion is an important modulator of 
the function of K+ and Ca2+ channels in the cardiac cell sarcolemma. Magnesium is also an essential 
component in the coupling of cardiac cell membrane receptors to G-proteins and second messanger 
systems inside the cell. Consequently, tissues that have an intense mitochondrial structure and a 
high enzymatic activity become especially vulnerable to changes in the cellular Mg2+ supply (White 
and Hartzell 1989, Rude 1989). 
3.1.3. Magnesium in the myocardium 
The exchangeable fraction of the total amount of Mg2+ in the myocyte is 98 %, and the rate of 
exchange between extracellular and intracellular Mg2+ has a T1/2 of 182 min and a flux of 0.21 
pmol/(cm2 x sec) (Page and Polimeni 1972). The intracellular uptake of Mg2+ is slow and depends 
on its extracellular concentration, with a 98% exchange within 20 hours (Page and Polimeni 1972, 
Flatman 1991). Under physiological conditions, Mg2+ is not in thermodynamic equilibrium across 
the sarcolemma, but there is an inward negative electrochemical gradient of about –15.3 kJ. While 
28Mg2+ uptake studies have revealed that the sarcolemma can be permeable to Mg2+  (Flatman 
1991), the pathways of the active transport system have remained unknown. A membrane-bound 
Mg2+/Mg2+ exchanger has not been identified. A Na+/Mg2+ exchange mechanism has been 
characterized in non-cardiac cells but not in the heart (Flatman 1991). In mammalian cells, specific 
voltage-gated channels for Mg2+ have not been detected, nor have Ca2+ or other channels been 
responsible for Mg2+ transport (White and Hartzell 1989, Freudenrich et al. 1996). However, -
adrenergic stimulation with rise in cyclic AMP can induce a substantial efflux of Mg2+ (Romani and 
Scarpa 1990). This process is quite rapid and can comprise about 20 % of the total cellular Mg2+.
Propranolol completely prevents the efflux (Romani and Scarpa 1990). Inside the cell, 
mitochondrial Mg2+ uptake probably takes place via an electrophoretic uniporter mechanism 
secondary to phosphate accumulation and efflux by respiration-dependent Mg2+/H+ exchange 
mechanism (Freudenrich et al. 1996). 
3.1.4. Determination of the body  magnesium status     
Hypomagnesemia, i.e., low serum concentration of Mg2+, and magnesium deficiency, i.e., decreased 
body magnesium store, are often misleadingly quoted as synonyms. Based on the physiology of 
Mg2+, hypomagnesemia and magnesium depletion may occur independently. Since only 1 % of 
Mg2+ is in the extracellular space the serum concentration of Mg2+ is an inappropriate method to 
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assess the total body Mg2+ content (Reinhart 1988). Consequently, a normal serum Mg2+ level does 
not exclude Mg2+ deficiency and a low serum level does not explicitly indicate depletion.  
3.1.4.1. Serum measurement 
The most common method to estimate the body Mg2+ level has been the measurement of its total 
serum concentration by atomic absorption spectrophotometry. Measurement of the diffusible, 
ionized Mg2+ concentration in the blood by an ion selective electrode has become available recently 
(Altura and Altura 1991-92, Lewenstam 1991). Values ranging between 0.53 and 0.67 mmol/l have 
been reported, representing about 71 % of the total blood Mg2+ in healthy subjects (Altura and 
Altura 1991). In pathophysiological states, deviations in the levels of ionized Mg2+, i.e., the active 
mode occur, while the total concentrations have remained unchanged (Altura and Altura 1991-92). 
The utility of this method as a diagnostic tool in clinical practice needs further investigations. 
3.1.4.2. Total body measurement 
A reliable estimation of the total body Mg2+ status can be made with the magnesium loading test 
(Jones et al. 1969). In the test, 30 mmol of Mg2+ is infused within 12 h at a constant rate, and the 
urinary excretion of Mg2+ during a period of 24 h from the start of the infusion is calculated. The 
proportion retained of the amount of Mg2+ administered determines the retention percentage. The 
bigger the retention percentage is, the greater is the deficiency. A retention of 30 % is widely 
accepted to indicate Mg2+ deficiency (Rasmussen et al. 1988, Goto et al. 1990).  
3.1.4.3. Intracellular measurements 
A low intracellular content of Mg2+ has been suggested as a measure of Mg2+ deficiency. The most 
common sources for material to determine the intracellular content of Mg2+ are circulating blood 
mononuclear cells, erythrocytes, and skeletal muscle tissue. For assessment of Mg2+ in mononuclear 
cells of the blood the cells are separated from peripheral venous blood, counted, and lysed (Elin and 
Johnson 1982). The total Mg2+ concentration is determined by using atomic absorption 
spectophotometry and protein measurement according to the method by Lowry and coworkers 
(1951). The results are expressed as fg/cell, g/mg of protein, or nmol/mg of protein, rarely as 
mmol/kg dry weight (Ryan et al. 1981), or pmol/100 cells (Abraham et al. 1986). Thus, in healthy 
subjects mean values ranging from 70.7 ± 14.1 to 80.6 ± 22.7 fg/cell (Elin and Hosseini 1985, Elin 
and Johnson 1982), from 1.18 ± 0.25 to 1.44 ± 0.35 g/mg of protein (Kulick et al. 1988, Ryzen et 
al. 1986, Elin and Johnson 1982), and from 48.5 ± 9.9 to 74.4 ± 16 nmol/mg of protein (Kulick et 
al. 1988, Ryzen et al. 1986, Sjögren et al. 1987) have been reported. Among patients with heart 
disease, concentrations of 278 ± 111 nmol/mg of protein or 86.2 ± 23.9 fg/cell in patients with 
dilative cardiomyopathy, and of 72.5 ± 24.2 nmol/mg of protein in patients with AMI have been 
found (Ralston et al. 1989, Urdal et al. 1992). The values have been 1.15 ± 0.02 g/mg of protein or 
47.3 nmol/mg of protein in coronary care unit patients, and 1.08 ± 0.03 g/mg of protein or 44.4 
nmol/mg of protein in congestive heart failure patients (Ryzen et al. 1986). A mean concentration of 
34.8 nmol/mg of protein has been reported in untreated patients with essential hypertension, and 
34.5-36.2 nmol/mg of protein after treatment of the same patients with different non-loop diuretic 
agents (Siegel et al. 1992).  
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The advantage of doing blood mononuclear cell determinations is that these are easily accessible 
by simple venous blood samples. Potential problems originate from the rather complex method 
itself and the characteristics of the mononuclear cells. The age distribution of the cells is variable, 
and this may influence the intracellular Mg2+ concentration (Elin and Johnson 1982). These factors 
cause substantial variability of the results (>25 % coefficient of variation in a healthy population) 
(Elin and Johnson 1982). The day-to-day variation for Mg2+ is 8.0 % expressed as the coefficient of 
variation (Sjögren et al. 1987). The use of leukocytes instead of mononuclear cells makes 
comparisons with mononuclear measurements inaccurate due to neutrophil contamination (Elin and 
Johnson 1982). Furthermore, rather than estimating true intracellular Mg2+ status, the mononuclear 
cell concentration may mirror the interstitial myocardial concentration and, thus, provide different, 
more dynamic information on the flux of Mg2+ from one body compartment to another (Abraham et 
al. 1986). The rather wide range for normal values and the time-consuming analytical process are 
further major drawbacks of this method. 
Skeletal muscle determinations are performed from samples obtained by percutaneous muscle 
biopsies, mostly from the vastus lateralis muscle, according to the method originally described by 
Bergström (1962). The concentration is expressed in units of nmol/mg of protein, mmol/100 g of fat 
free dry solids, and mol/g of wet weight tissue. In healthy subjects, mean concentrations of 9.5 ± 
0.2 mol/g of wet weight (Dørup et al. 1988), or 4.22 ± 0.16 - 4.42 ± 0.39 mmol/100 g of fat-free 
dry solids (Sjögren et al. 1987, Dyckner and Wester 1987c) have been reported. Low values have 
been identified in patients on diuretic therapy for arterial hypertension, 5.8 ± 0.5 mol/g of wet 
weight (Dørup et al. 1988), or 4.06 ± 0.59 mmol/100 g of fat free dry solids (Dyckner and Wester 
1987c), and in patients with heart failure, 76.7 ± 19.9 nmol/mg of protein (Ralston et al. 1989). The 
invasiveness limits the use of this technique, and hampers its utility in studies necessitating 
successive determinations. 
Other measurements of the intracellular concentration of Mg2+ are less common. Mean values for 
erythrocyte Mg2+ concentration in healthy subjects of 0.038 ± 0.001 fmol/100 cells (Abraham et al. 
1985) and 2.05 ± 0.33 – 2.20 ± 0.47 mmol/l (Sjögren et al. 1987) have been reported. A novel 
technique, energy-dispersive x-ray analysis, has yielded a value of 37.9 ± 4.0 mEq/l (18.9 ± 2.0 
mmol/l) for normal values for total Mg2+ in sublingual epithelial cells (Haigney et al. 1995, 
Shechter et al. 2000). 
3.1.4.4. Estimation of the myocardial magnesium content 
Most of the Mg2+ in mammalian cardiac cells is bound to membranes and proteins, or sequestered 
in organelles. The intracellular concentration of ionized Mg2+, the physiologically active form, is 
estimated to range between 0.4 and 3.5 mmol/l (White and Hartzell 1989, Freudenrich et al. 1996). 
In patients with coronary artery disease undergoing surgical revascularization, total median 
myocardial levels of 2.60 - 7.66 mol/g of wet weight (MØller Jensen et al. 1991) and total mean 
values of 16 ± 0.15 mmol/l (Haigney et al. 1995), 67 ± 15 nmol/mg of protein (Ralston et al. 1989), 
or from 103 ± 13 to 111 ± 10 g/g of wet weight (Reinhart et al. 1991) have been reported. Many 
Mg2+-cofactored enzyme-substrate reactions in the cell have their Km values (the substrate 
concentration producing half-maximal velocity for the reaction) for Mg2+ within the observed 
limits, which implies that physiological fluctuations in the intracellular Mg2+ content can 
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significantly modulate the respective processes (White and Hartzell 1989).  
3.1.4.5. Relation between different determinations 
In most studies, serum Mg2+ levels have not correlated with intracellular values, not in healthy 
subjects nor in patients with various cardiovascular diseases (Ryzen et al. 1986, Reinhart 1988, 
Ralston et al. 1989, Haigney et al. 1995). Furthermore, serum ionized and total Mg2+ concentrations 
correlate poorly (Altura and Altura 1991-92). A good correlation between mononuclear cell and 
skeletal muscle Mg2+ concentrations has been reported in healthy subjects (Dyckner and Wester 
1985, Sjögren et al. 1987) but not in patients with heart failure (Dyckner and Wester 1987a, Ralston 
et al. 1989). Experimentally, serum and lymphocyte Mg2+ concentrations decreased in parallel 
during diuretic treatment in rats, but these reductions were not accompanied by concomitant 
changes in skeletal muscle or cardiac cell Mg2+ contents (Wong et al. 1988). The discrepancy 
between the results on healthy subjects and patients with a heart disease may be explained by 
deterioration in the ionic transport across the mononuclear cell membrane, or by increased fragility 
of the membrane, secondary to the underlying heart disease. Also, the lifespan of the mononuclear 
might be shortened in heart failure (Dyckner and Wester 1987a). 
Knowledge of the myocardial Mg2+ content would be of extraordinary interest in clinics but, thus
far, there are no conclusive data. While direct measurement of myocardial Mg2+ is mostly 
unattainable, investigations have focused on testing surrogate tissues which would reflect cardiac 
levels. In this respect, no data regarding healthy subjects are available. Serum Mg2+ levels do not 
predict the Mg2+ content of the myocardium of patients with a heart disease (Reinhart 1988, Ralston 
et al. 1989, MØller Jensen et al. 1991). Furthermore, Ralston and coworkers (1989) found no 
relation between skeletal muscle or circulating mononuclear cell and myocardial Mg2+ in a 
population of ambulatory heart failure patients. Skeletal muscle and right atrial Mg2+ concentrations 
have, according to one study, shown an association (MØller Jensen et al. 1991). Reinhart and 
coworkers (1991) studied myocardial Mg2+ contents in samples obtained from the right atrial 
appendage of patients undergoing cardiac surgery, and found no correlation with serum total or 
blood mononuclear cell Mg2+. However, in severely ill patients the mononuclear cell concentration 
predicted the atrial concentration with a weak but statistically significant accuracy. Haigney and 
coworkers (1995) reported a good correlation between sublingual cell and myocardium Mg2+
concentrations obtained from right atrial biopsy specimens in patients undergoing CABG. 
Moreover, the Mg2+ concentration of their healthy control patients corresponded well with reported 
normal values in mammalian myocardium (Polimeni and Page 1973, Haigney et al. 1995). In Mg2+
deficient rats, losses of Mg2+ from lymphocytes parallels losses from cardiac muscle (Ryan and 
Ryan 1979). Wong and coworkers (1988) did not find a relationship between cardiac muscle and 
other intracellular or serum concentrations of Mg2+.
Experimental and clinical studies have suggested that Mg2+ is more readily exchangeable in the 
myocardium than in skeletal muscle, where it is strongly bound. Thus, acute alterations measured 
from skeletal muscle samples may become imprecise (Page and Polimeni 1972). While the skeletal 
muscle content might reflect stable conditions in the myocardium, mononuclear cells, owing to their 
short lifecycle, may show acute changes more precisely (Dyckner and Wester 1985).  
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3.2. Hypomagnesemia and magnesium depletion associated with cardiovascular 
disorders 
3.2.1. General 
The causes of magnesium deficiency comprise both physiological and pathophysiological 
conditions: 1. reduced intake, as in starvation and prolonged intravenous therapy with supplements 
lacking of Mg2+; 2. impaired intestinal absorption, as in chronic diarrhea, or malabsorption, and a 
specific familial form; 3. excessive renal loss, as in inadequately treated diabetes mellitus, use of 
thiazide and loop diuretics, or antibiotics such as gentamicin and carbenicillin, hyperosmotic states 
such as hyperglycemia, alcohol use, cisplatin and cyclosporine medication, hyperparathyroidism 
and other hypercalcemic states, renal tubular acidosis, and postobstructive diuresis; 4. 
cardiovascular morbidity; and 5. miscellaneous states such as excessive sweating, and idiopathic 
hypomagnesemia (Reinhart 1988). 
The normal magnesium balance is largely dependent on the intake of magnesium-rich food, e.g., 
green leafy vegetables, fish, whole grains and nuts, the consumption of which is too small in the 
current western diet. It has been stated that individuals with normal food intake cannot be 
magnesium deficient (Seelig 1989). Diets containing high amounts of saturated fats (by forming 
soaps in the intestine), excessive sugar consumption (by osmotic magnesiuresis), a high Ca2+/Mg2+ 
ratio in the diet, and excess alcohol use (by osmotic magnesiuresis, combined with a low intake and 
secondary aldosteronism) favor Mg2+ depletion (Seelig 1989). Pregnancy, growth, aging, stress, and 
other conditions with sympathetic overactivity raise the Mg2+ requirement (Harper 1973, Reinhart 
1988, Seelig 1989). Conversely, living in areas with Mg2+ rich soil, represented as “hard“ water, has 
been associated with prophylaxis of Mg2+ deficiency (Anderson et al. 1975, Karppanen 1981). 
3.2.2. Cardiovascular mortality and sudden cardiac death 
Epidemiologically, the rates of total cardiovascular and sudden cardiac death are associated 
inversely with the Mg2+ content in drinking water, i.e., water hardness (Sharret and Feinleib 1975, 
Anderson et al. 1975, Neri and Johansen 1978, Karppanen 1981). In addition, there may be an 
association between death from AMI and a reduced myocardial Mg2+ concentration (Anderson et 
al. 1978). Experimentally, complete elimination of Mg2+ from diet leads to the death of animals 
within months (Whang and Welt 1963, Wener et al. 1964). While the mechanisms of sudden 
cardiac death are incompletely understood, focal myocardial necrosis, small vessel changes 
(Whang and Welt 1963, Wener et al. 1964, Iseri and French 1984), and spatially heterogenous 
prolongation of ventricular repolarization with induction of polymorphic nonsustained tachycardia 
(Fiset et al. 1996) occur in association with Mg2+ deficiency in animal studies.  
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3.2.3. Acute myocardial infarction 
A transient decline in the serum Mg2+ concentration takes place in 6 to 46 % of the patients with 
AMI (Abraham et al. 1977, Dyckner 1980, Rasmussen et al. 1986b, Kafka et al. 1987). The 
reduction occurs already a few hours after the onset of the infarction and the concentration is 
normalized in two weeks (Abraham et al. 1977, Dyckner 1980, Rasmussen et al. 1986b, Madias et 
al. 1996). Serum Mg2+ levels start to rise already upon transfer of the patients from the emergency 
department to the coronary care unit (Madias et al. 1996). Consistent with this, intracellular Mg2+
concentrations begin to increase already 24 h after the start of the infarct (Haigney et al. 1995). In 
contrast, there are also reports where serum and intracellular Mg2+ levels have not fallen at all (Ellis 
and Walmsley 1988, Urdal et al. 1992, Haigney et al. 1995).  
The decline in the serum Mg2+ concentration following AMI is probably explained by a shift 
between magnesium compartments in the body. In this, catecholamine oversecretion plays a major 
role. In vivo, infusions of adrenaline and salbutamol cause a fall in the serum Mg2+ level (Whyte et 
al. 1987, Ryzen et al. 1990), and propranolol, but not phentolamine inhibits this fall (Rayssiguier 
1977). The reduction is not accounted for by a movement of Mg2+ from the serum into circulating 
blood cells, or by increased renal secretion (Rasmussen et al. 1986b, Ryzen et al. 1990). 
Catecholamine-induced lipolysis with aggregation of Mg2+ with free fatty acids leads to 
sequestration of Mg2+ in adipocytes, and explains partly the observed hypomagnesemia (Elliot and 
Rizack 1974, Rayssiguier 1977, Flink et al. 1981). The catecholamine effect is not unique to AMI 
but all acutely stressful conditions may be accompanied by hypomagnesemia (Chernow et al. 1989). 
In conformity with this, Ryzen and coworkers (1986) demonstrated lowered blood mononuclear cell 
Mg2+ levels in unselected patients treated in the intensive cardiac care unit. 
In AMI, hypomagnesemia may imply myocardial Mg2+ depletion. In comparison with non-
infarction CCU patients and healthy subjects, there is a reduced total Mg2+ concentration in the 
sublingual cells of AMI patients in CCU (Haigney et al. 1995); the sublingual cells provide the best 
surrogate information on the total myocardial Mg2+ level. In agreement with this, increased Mg2+
retention has been reported among AMI patients (Urdal et al. 1992). In experimental infarction 
models, ligation of a coronary artery leads to Mg2+ loss from the myocardium (Iseri et al. 1952). In 
isolated cultured rat ventricular myocytes, hypoxia of even a short duration without cell injury 
results in the loss of cytoplasmic Mg2+. This is further aggravated during persistent ischemia and 
injury (Thandroyen et al. 1992). In agreement with in vivo studies, perfusion of rat hearts and 
isolated rat ventricular myocytes with noradrenaline results, through a rise in cyclic AMP, in a large 
efflux of Mg2+ from the cardiac cells (Romani and Scarpa 1990, Romani et al. 1993). This efflux is 
entirely prevented by -adrenergic but not by α-adrenergic blockade (Romani and Scarpa 1990). 
It has also been proposed that hypomagnesemia and Mg2+ depletion antecede the development of 
myocardial infarction. In support of this hypothesis, depressed myocardial Mg2+ concentrations 
have been reported in patients who have died of myocardial infarction (Speich et al. 1980). 
Furthermore, dogs kept on a Mg2+ poor diet experience enlarged necrosis following experimental 
AMI (Chang et al. 1985). The potential mechanisms explaining these observations include 
vasospasm (Turlapaty and Altura 1980), increased platelet aggregation (Adams and Mitchell 1979), 
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and impaired recovery from ischemia (Borchgrevink and Jynge 1987). 
3.2.4. Heart failure 
Hypomagnesemia and Mg2+ depletion are frequently encountered in patients with heart failure, and 
the presence of low Mg2+ indicates a worse prognosis than among patients with a normal Mg2+
status (Gottlieb et al. 1990), though not consistently (Eichhorn et al. 1993). Low serum Mg2+ levels 
have been reported in up to 38 % of the patients (Wester and Dyckner 1986, Ralston et al. 1989, 
Gottlieb et al. 1990, Perticone et al. 1990, Eichhorn et al. 1993, Sueta et al. 1994, Ceremuynski et 
al. 2000). Among 104 unselected coronary care unit patients, those with heart failure had 
significantly reduced mononuclear cell Mg2+ levels and this was independent of diuretic therapy 
and any heart disease (Ryzen et al. 1986). Haigney and coworkers (1998) used a rapid pacing-
induced heart failure model and demonstrated a significant total and ionized Mg2+ loss from the 
myocardium of untreated dogs. Furthermore, the same group showed that subjects with a low left 
ventricular EF and ventricular arrhythmias had decreased tissue Mg 2+ levels together with increased 
QT interval dispersion (Haigney et al. 1997). Also necropsy studies have shown that the myocardial 
Mg2+ concentrations in patients with heart failure are low (Iseri et al. 1951, Elwood et al. 1980). 
Magnesium depletion itself may conceivably cause cardiomyopathy (Heggtveit et al. 1964, Iseri and 
French 1984).  
Factors contributing to the genesis of hypomagnesemia and Mg2+ depletion consist of 
neurohormonal activation and pharmacological treatment of the disease (especially use of diuretics 
and digoxin). A low cardiac output with redistributed circulation results in diminished renal blood 
flow and this activates compensatory vasoconstrictive and volume expanding mechanisms. Of the 
first, elevated catecholamine excretion can cause hypomagnesemia. Of the second, activation of the 
renin-angiotensin-aldosterone system can increase the renal excretion of Mg2+ indirectly (Horton 
and Biglieri 1962, Wester and Dyckner 1986, Gottlieb 1989). Furthermore, the aldosterone and 
vasopressin-induced fluid retention and consequent expansion of the extracellular volume result in 
reduced Mg2+ reabsorption from the proximal renal tubule (Wester and Dyckner 1986, Gottlieb 
1989). Volume expansion also leads to intestinal edema with a reduced absorption of Mg2+, further 
aggravated by malnutrition following nausea and anorexia (Gottlieb 1989). Of pharmacological 
treatments, thiazide and loop diuretics can cause hypomagnesemia and Mg2+ deficiency (Chapter 
3.2.7).
Hypomagnesemia and Mg2+ depletion maintain the vicious circle of the pathophysiology of heart 
failure. Low serum Mg2+ level stimulates renin release (Wester and Dyckner 1986). As Mg2+ is a 
mandatory co-factor of Na+-K+-ATPase, the hyperaldosteronism-induced cellular Na+ accumulation 
and K+ loss are insufficiently counteracted by the pump and, thus, the Na+/Ca2+ counter transport 
will be increased, leading to intracellular accretion of Ca2+. Calcium overload in the failing heart 
may cause additional deterioration of the ventricular pump and trigger ventricular arrhythmias 
(Wester and Dyckner 1986, White and Hartzell 1989). 
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3.2.5. Coronary artery disease 
Magnesium depletion might lead to atherosclerosis (Seeling and Heggviet 1974, Bloom 1985). 
Depressed myocardial Mg2+ levels have been found postmortem in patients with ischemic heart 
disease (Elwood and Beasley 1981). Recently, an inverse relation between the serum concentration 
of Mg2+ and the incidence of coronary heart disease has been observed in two prospective 
epidemiologic studies (Gartside and Glueck 1995, Liao et al. 1998). A low dietary magnesium 
intake correlates significantly with the incidence of ischemic heart disease only by univariate 
analyses, with a substantial reduction in the predictive value after correction for other known risk 
factors (Elwood et al. 1996). In vitro, Mg2+ deficiency produces endothelial changes and constricts 
the coronary arteries (Turlapaty and Altura 1980, Orimo et al. 1990). Furthermore, Mg2+ inhibits the 
tonic and the periodic contractions of human coronary arteries induced by prostaglandin F2α in vitro 
as effectively as diltiazem and nitroglycerin (Kimura et al. 1989). Clinically, magnesium loading 
tests have shown that patients with atherosclerotic coronary artery disease and vasospastic angina 
are Mg2+ deficient (Rasmussen et al. 1988, Igawa et al. 1995). Shechter and coworkers (2000) 
demonstrated depressed intracellular Mg2+ concentrations in patients with stable chronic coronary 
artery disease. 
3.2.6. Cardiac surgery 
Cardiac surgery where cardiopulmonary bypass is utilized leads to a postoperative decline in serum 
Mg2+ levels (Bunton 1983, England et al. 1992, Zaman et al. 1997). Scheinman and coworkers 
(1969) found true hypomagnesemia in every patient after the operation. England and coworkers 
(1992) showed a 90 % prevalence of total and a 50 % prevalence of ultrafilterable serum 
hypomagnesemia shortly after the operation. The serum Mg2+ concentration starts to fall just prior 
to the onset of the operation, reaches its nadir after cessation of the extracorporeal circulation, and 
regains the preoperative level by the fourth postoperative day (Bunton 1983, England et al. 1992, 
Casthely et al. 1994, Fanning et al. 1991, Zaman et al. 1997, Speziale et al. 2000). 
The reports elucidating the intracellular Mg2+ alterations following cardiac surgery are few. 
Haigney and coworkers (1995) reported low intracellular total Mg2+ concentrations without any 
concomitant reduction in its serum levels. However, Møller Jensen and coworkers (1997) reported 
no change in the skeletal muscle concentrations of Mg2+ on the third postoperative day after CABG.  
The proposed causes for the decline in serum Mg2+ concentration following cardiac surgery are 
hemodilution, use of diuretics, secondary hyperaldosteronism, increased anabolic activity and 
enhanced sympathetic activity (Vejlsted and Eliasen 1978, Rasmussen et al. 1986b, Whyte et al. 
1987, Kalman et al. 1992). There is experimental evidence for sequestration of Mg2+ into adipose 
tissue (Flink et al. 1981), but no evidence for an acute intracellular shift (Ryzen et al. 1990). 
Increased urinary secretion of Mg2+ has not been demonstrated, making true Mg2+ loss unlikely 
(Vejlsted and Eliasen 1978, Rasmussen et al. 1986b). 
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3.2.7. Treatment with diuretics 
Long-term treatment with thiazide or loop diuretics gives rise to hypomagnesemia and Mg2+
depletion (Ryan et al. 1981, Sheehan and White 1982, Wester and Dyckner 1986, Dyckner and 
Wester 1987c, Dørup et al. 1988). Due to the interrelationship between the metabolisms of Mg2+
and K+, the incidence of concomitant hypomagnesemia in the presence of hypokalemia may be as 
high as 42 % (Whang et al. 1984). Magnesium depletion, in terms of subnormal tissue levels has 
been found in 43 % of subjects on diuretic treatment (Dyckner and Wester 1987b, Dyckner and 
Wester 1987c). On the other hand, the use of K+ (and Mg2+) sparing diuretics and angiotensin 
converting enzyme inhibitors, or the use of a short-term hydrochlorothiazide therapy probably 
prevents the development of hypomagnesemia and Mg2+ depletion (Ralston et al. 1989, Siegel et al. 
1992). The effect of diuretics takes place in the portion of the nephron where most of the filtered 
Mg2+ is absorbed (Dyckner and Wester 1987). The excess loss of Mg2+ through the kidneys is 
further enhanced by diuretic-induced activation of the renin-angiotensin-aldosterone system, 
hypochloremia and metabolic alkalosis (Horton and Biglieri 1962).  
Long-term treatment with diuretics may predispose the patient to ventricular arrhythmias. If 
hydrochlorothiazide treatment leads to marked hypomagnesemia, the occurrence of VPBs correlates 
with the decrease in serum Mg2+ levels (Hollifield 1984). In the Multiple Risk Factor Intervention 
Trial, hypertensive subjects with electrocardiographic abnormalities and thiazide treatment were 
more prone to sudden death than subjects without this treatment (Multiple Risk Factor Intervention 
Trial Research Group 1985). However, Siegel and coworkers (1992) did not find an association 
between serum or intracellular Mg2+ concentrations and ventricular arrhythmias in hypertensive 
outpatients treated with either hydrochlorothiazide alone or combined with a K+ and Mg2+ sparing 
diuretic treatment, and others have suggested that the use of Mg2+ and K+ sparing regimens may 
even improve prognosis (Amery et al. 1985). 
The association of hypomagnesemia and magnesium depletion with the development of cardiac 
arrhythmias will be discussed in detail in chapter 3.3.4. 
3.3. Magnesium and cardiac arrhythmias 
3.3.1. Electrophysiology of the cardiac cell 
3.3.1.1. Action potential, excitation and conduction 
The electrical potential difference across the semipermeable cardiac cell membrane, i.e., the resting 
membrane potential, is mainly due to the operation of the Na+-K+ pump, which grabs K+ into the 
cell and extrudes Na+. The potassium ion is the single most significant determinant of the multi-
ionic transmembrane potential. Upon stimulation, the initial negative charge of the cell interior is 
abruptly transposed to a positive value, after which it regains its negativity gradually. This 
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stereotypical depolarization-repolarization sequence, the action potential, is unique to different 
regions of the heart. In the ventricular muscle, the initial rapid depolarization (overshoot, phase 0) is 
followed by a distinct phase of fast repolarization, most prominent in the Purkinje cells (phase 1). 
Phase 2 comprises a mixture of maintained depolarization and slow repolarization (plateau or 
dome). Phase 3 features a more rapid, final repolarization, ending in the diastolic or resting potential 
(phase 4) (Rudy 2000). The duration of repolarization is shorter in the endocardial than epicardial 
cells, and longest in the deep mid-myocardium, the M cells (Antzelevitch and Sicouri 1994). 
The cardiac action potential is generated by transient flow of Na+, K+, Ca2+ and chloride ions 
through sarcolemmal ion channels. Inwardly directed, depolarizing currents, are predominately 
carried by Na+ and Ca2+ and outward, repolarizing currents, by K+ and chloride ions. Repolarization 
is mainly formed by several outward K+ currents carried through respective K+ channels. Of these, 
the rapidly activating (IKr) and the slowly activating (IKs) delayed rectifier and the transient outward 
potassium current (Ito) operate during the plateau through to the end of repolarization. The inward 
rectifier (IK1) contributes to the maintenance of the resting potential as well. Furthermore, the Ca2+ -
sensitive, Na+ -sensitive, ATP-sensitive and acetylcholine-sensitive K+ channels contribute to the 
electrical activity of the myocyte (Rudy 2000). 
Normal atrial and ventricular muscle and Purkinje cells can not be reexcited during phases 0 to 2, 
i.e., they are refractory to any stimulus, regardless of their strength (absolute refractoriness, 
effective refractory period). During the repolarization phase 3 the cell can be excited provided an 
intense stimulus is used (relative refractoriness). Electrophysiologically, refractoriness is a function 
of the recovery of the activity of the fast Na+ channels. This recovery is voltage dependent and, 
thus, determined by the operators of repolarization, i.e., inactivation of the slow inward current 
along with activation of the outward K+ currents (Rudy 2000). 
The properties of the fast Na+ channels form the physiological basis for excitation and 
conduction and also for the pathogenesis of arrhythmias involving impulse propagation and 
conduction, i.e., reentry. A disturbance in the intracellular handling of Ca2+ may lead to arrhythmias 
generated by abnormal automaticity or afterdepolarizations. Proper function of the K+ channel 
family is mandatory for solid repolarization, and disruption in the operation of one channel can give 
rise to life-threatening ventricular arrhythmias evoked by afterdepolarizations or reentry. 
3.3.1.2. Measurement of the action potential in humans 
The monophasic action potential is an extracellularly registered signal from the epicardium or 
endocardium of the heart beating in situ (Burdon-Sanderson and Page 1882). The original 
characterizations were performed by use of suction electrode catheters (Jochim et al. 1935, Schütz 
1936, Hoffman et al. 1959, Korsgren et al. 1966). Their applicability in clinical science was 
limited to short recording periods only due to the risk of subendocardial damage and ST segment 
elevation. Afterwards, the contact electrode catheter technique has been introduced and validated 
allowing long term, safer and more stable recordings (Franz et al. 1980, Franz 1983). The obtained 
wave forms resemble closely the shape and duration of intracellular registrations (Franz 1991). 
The MAP signal is hypothesized to represent the electrical gradient between mechanically 
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depolarized myocytes subjacent to the recording electrode and adjacent intact cells (Franz 1991). 
The resulting resting membrane potential is, however, lower and the amplitude and the maximal 
upstroke velocities are smaller compared to the action potentials measured by intracellular 
microelectrodes (Franz 1991). Despite variations in the morphology and genesis between 
transmembrane and extracellular recordings, the responses are similar regardless if they are 
induced by altering extracellular electrolyte levels and pacing cycle length, or by pharmacological 
interventions and ischemia (Platia et al. 1988, Franz 1991). Thus, MAP recording is regarded as an 
appropriate technique for providing local information from the myocardium about depolarization 
and repolarization.  
3.3.2. Magnesium in the electrophysiology of the cardiac cell 
3.3.2.1. Role in physiology  
The magnesium ion serves as a major regulator of the electrical and mechanical function in the 
cardiac cell. The transmembrane ion flux through specific ion channels is modified by Mg2+. It is 
also an essential co-factor for the membrane-bound Na+-K+-ATPase and Ca2+-ATPase. Signal 
transfer from the outside to the inside the cell via G-protein activity is modulated by Mg2+. Mg2+
contributes to the cellular Ca2+ homeostasis and further to contractile function by modulating Ca2+
release from the sarcoplasmic reticulum and Ca2+ uptake by the mitochondria. Finally, it is an 
essential co-factor for many enzymes involving energy production and utilization: most of the 
intracellular ATP is complexed with Mg2+, and ATP cannot be utilized in energy production 
without Mg2+ (White and Hartzell 1989, Freudenrich et al. 1996). 
3.3.2.2. Modulation of ion channel function 
The magnesium ion can affect ion channel function both extracellularly and intracellularly. 
Extracellularly, Mg2+ may enter the channel and decrease the respective current amplitude. Mg2+
may also alter the membrane surface charge and thus, affect the voltage-dependence behavior of the 
channel (Agus and Morad 1991). Intracellularly, Mg2+ controls inward rectification of at least four 
different K+ channels and modulates some outwardly directed currents (Agus and Morad 1991).  
Inward rectification of K+ channels, i.e., allowance of K+ passage from the outside to the inside 
the cell and prevention of the opposite movement, plays an important role in the maintenance of the 
duration of the plateau and in the rapid repolarization of the action potential, as well as in 
determining the resting membrane potential (Agus and Morady 1991, Hartzell 1996). In the case of 
the inward rectifier K+ current (IK1), Mg2+ blocks the open channel from the cytoplasmic surface of 
the ventricular cell membrane (Matsuda et al. 1987, Vandenberg 1987). The process is rapid and 
voltage-dependent, i.e., it requires depolarization. Mg2+ operates optimally at a concentration of 0.5 
mM, which is well within its physiological range, and if Mg2+ is extremely depleted dysfunction 
may ensue (Vandenberg 1987). 
Inward rectification of the ATP-sensitive K+ channel (IK(ATP)), which is activated by intracellular 
ATP depletion in atrial and ventricular cells, is blocked by intracellular Mg2+ (Horie et al.. 1987). 
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Ischemia uncouples Mg2+ from complexing with ATP and this prevents the outward K+ current 
through this channel (White and Hartzell 1989). 
Receptor-activated, humorally mediated inward rectification through the muscarinic K+ channel 
(IK(ACh)) is controlled by cytocolic Mg2+ in atrial, pacemaker, and Purkinje cells (Horie and Irisawa 
1987). In addition to inward rectification, acetylcholine stimulation also activates G-protein 
function, a process also under the control of cytosolic Mg2+ (Brown and Birnbaumer 1988, White 
and Hartzell 1989).  
The magnesium ion influences the voltage-dependent Ca2+ current in several ways. Internal Mg2+
inhibits the slow inward (dihydropyridine-sensitive, L-type) Ca2+ current by modulating the 
phosphorylation of the channel protein. This inhibition is only moderate under basal conditions, but 
substantially increased when the current is first stimulated by isoprenaline to increase the 
intracellular cAMP (White and Hartzell 1988). The interaction between the negatively charged 
surface of the cell membrane and, possibly, the channel protein itself shifts the voltage sensitivity of 
the channel to more depolarized potentials. Mg2+ also competes with Ca2+ for entrance through the 
channel (Hall and Fry 1992).  
3.3.2.3. Regulation of intracellular calcium 
In addition to Ca2+ influx, Mg2+ also modulates the intracellular availability and handling of Ca2+.
Although Mg2+ is an obligatory co-factor for the activity of the sarcolemmal Ca2+-ATPase and 
sarcolemmal Na+-Ca2+ exchange mechanism, their affinity for Mg2+ is saturated already below the 
range of the physiological intracellular Mg2+ concentration, making it unlikely for Mg2+ to be of 
regulatory significance (White and Hartzell 1989). On the other hand, the sarcoplasmic reticulum 
membrane Ca2+-ATPase is sensitive to fluctuations of intracellular Mg2+ within its physiological 
range (Chiese et al. 1981). Also the capability of cardiac muscle mitochondia to buffer Ca2+ seems 
to be affected by physiological intracellular Mg2+ concentrations (White and Hartzell 1989). Since 
the primary mechanism to regulate the mammalian cardiac cell Ca2+ is to control its accumulation 
in and release from the sarcoplasmic reticulum, intracellular Mg2+ affects the cellular Ca2+
homeostasis in an important way (White and Hartzell 1989).  
3.3.2.4 Low extracellular magnesium and magnesium depletion 
Hoffman and Suckling (1956) were the first to study experimentally the effect of low Mg2+ on the 
cardiac action potential. They used isolated canine papillary muscles and transmembrane action 
potential recordings and demonstrated that in the presence of a normal Ca2+ concentration in the 
superfusing solution a reduced Mg2+ concentration had no effect on the action potential. Very low 
Ca2+ concentrations caused a marked increase in the duration of the action potential, which was 
further prolonged by excluding Mg2+ totally. 
Watanabe and Dreifus (1972) recorded action potentials in isolated perfused rabbit hearts and 
found that a low Mg2+ concentration in the perfusate produced a shortening of the action potential 
duration, accompanied by a strong tendency toward decreases in membrane resting potential, action 
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potential amplitude and maximal rate of depolarization. Furthermore, stimulation during the relative 
refractory period repeatedly produced ventricular fibrillation (VF) when the ventricular excitability 
was tested. Surawicz and coworkers (1961) used the same animal model with ventricular MAP 
recording by suction electrodes, and found that perfusates devoid of Mg2+ caused no change in the 
shape or duration of the ventricular MAP. When the perfusates lacked Mg2+, the increase in the 
MAP duration induced by Ca2+-free perfusions was significantly accentuated. Concordant but less 
pronounced effects were observed when the Ca2+ concentration reduced to a smaller degree.  
ECG alterations have been documented in patients with Mg2+ deficiency but whether these 
alterations really are produced by Mg2+ depletion or as a result of a combination of various 
electrolyte disorders is unclear. Animal experiments have shown that acute Mg2+ deficiency 
produces no changes in ECG intervals (Grantham et al. 1960, Surawicz et al. 1961). Data obtained 
from isolated rabbit heart preparations show that profound Mg2+ depletion aggravates the 
prolongation of the QT interval secondary to experimental hypocalcemia (Surawicz et al. 1961). 
Haigney and coworkers (1997) have shown that QT dispersion correlates inversely with tissue Mg2+ 
levels in patients with ventricular arrhythmias. 
3.3.2.5. High extracellular magnesium 
In the experimental study by Watanabe and Dreifus (1972) elevation of the Mg2+ concentration in 
the perfusate led to lengthening of the ventricular action potential duration. Furthermore, the 
membrane resting potential and maximal rate of depolarization tended to increase and the 
atrioventricular (AV) conduction time was significantly prolonged. The VERP was also 
significantly prolonged.  
The effect of Mg2+ is more evident if the action potential is modified pharmacologically or by a 
disease. Mg2+ almost totally counteracts the lengthening of MAP generated by low Ca2+
concentrations in a concentration-dependent way (Surawicz et al. 1961). Moreover, Mg2+ shortens 
the action potential prolonged by quinidine in isolated canine Purkinje fibers (Davidenko et al. 
1989). The same is true for the MAP duration prolonged by d-sotalol in anesthetized dogs (Vos et 
al. 1995). In ischemia in humans, very early MAP prolongation is eliminated by Mg2+ (Redwood et 
al. 1996), and later shortening is reversed by it (Kraft et al. 1980). In cardiac transplant patients, 
Mg2+ tends to prolong the MAP duration (Millane et al. 1992).
3.3.2.6. Role in excitability, conduction and contractility 
When the concentration of extracellular Mg2+ is raised the excitability and conduction is reduced in 
isolated cardiac muscle preparations (Hall and Fry 1992). This is due to an increase in the 
depolarization threshold and a reduction in the conduction velocity of such hyperpolarized action 
potentials. This response may be explained by an influence of Mg2+ on the voltage dependence of 
Ca2+ and Na+ channels (Hahin and Campbell 1983). Furthermore, the conductance in gap junctions 
is depressed by a high concentration of extracellular Mg2+ (Noma and Tsuboi 1987).  
Studies of the effect of Mg2+ on contractility have revealed varying results depending on the 
experimental setting. Thus, in isolated ventricular myocytes, a negative inotropic effect by raised 
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extracellular Mg2+ levels has been observed. The response is due to a decrease in the voltage-
dependent slow Ca2+ current, possibly mediated by changes in the availability of Ca2+ for 
contraction, not by a change in the sensitivity of the contractile proteins to Ca2+ (Hall and Fry 
1992). In perfused heart preparations and intact hearts, Mg2+ exerts a positive inotropic effect, 
which is probably secondary to relaxation of the arterial smooth muscle and increased coronary 
blood flow (Vigorito et al. 1992). 
3.3.3. Mechanisms of arrhythmias 
3.3.3.1. Basic mechanisms 
Abnormal impulse conduction. Reentry is a mode of cardiac excitation, where a propagating 
impulse is not extinguished after activation of the myocardium, as it should, but continues to reenter 
after a refractory period. Reentry requires an area of unidirectional conduction block. When such an 
area evolves, conduction along an alternative pathway may be maintained, resulting in delayed 
activation of the area behind the block with retrograde conduction across this area. If the excitability 
of the region proximal to the block is recovered, reexcitation of the anterograde part of the loop 
occurs. Electrophysiologically, depressed action potential upstroke and partially depolarized 
transmembrane potential account for the slowing conduction, and variable refractoriness in 
neighboring areas (inhomogeneity in refractoriness) may induce a local block of premature 
depolarizations. Reentry is the leading mechanism of arrhythmias after remote AMI and in 
tachycardias involving anatomical AV pathways (Wit and Rosen 1989). 
Abnormal impulse initiation. Normal automaticity is the function of the conventional 
pacemaker of the heart, as well as a property of cells capable of acting as subsidiary pacemakers. 
Normal automaticity is generated after the spontaneous phase 4 depolarization, inherent to these 
cells (Wit and Rosen 1989). Abnormal automaticity arises in cells and fibers where the maximal 
diastolic membrane potential is significantly reduced, as may happen in ischemic atrial or 
ventricular cells, and in digitalis toxicity. A change in the balance between inward and outward 
currents and suppression of the Na+-K+ pump give rise to a spontaneous gradual decline in the 
diastolic resting potential and consequent arrhythmias. Factors that increase the intracellular Ca2+ or 
decrease the extracellular K+ level may uncouple a non-pacemaker cell from the suppressive control 
of the normal pacemakers. Arrhythmias arising by this mechanism may be fast, parasystolic or 
incessant, and only poorly overdrive-suppressed, and they may trigger reentrant tachycardias (Wit 
and Rosen 1989). 
Oscillations in membrane potential during phases 2 - 4 of the action potential are called 
afterdepolarizations and they may generate triggered activity. Oscillations are called EADs if they 
arise during repolarization, and delayed afterdepolarizations after completion of repolarization. 
When the amplitude of the afterdepolarization reaches a critical threshold potential level, a 
depolarization or a series of depolarizations is generated, and the ensuing tachyarrhythmia is called 
triggered. Afterdepolarizations are induced by the preceding action potential; they do not occur 
spontaneously (Wit and Rosen 1989). 
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EADs are caused by conditions that increase the inward current or decrease the outward current. 
EADs arising during the plateau phase are primarily generated by the slow inward Ca2+ current and 
those arising during phase 3 by suppression of the outward repolarizing K+ currents (Rosen 1994). 
The occurrence of EADs is favored by factors that prolong the repolarization phase, increase the 
inward Ca2+ current, or block the outward K+ currents. Thus, a deceleration of heart rate, 
catecholamine influence, ischemia, and K+ channel blocking drugs would promote torsade de 
pointes (TdP) polymorphous ventricular tachycardia (VT), the clinical manifestation of triggered 
activity (Wit and Rosen 1989, Rosen 1994). 
Delayed afterdepolarizations are generated by an overload of intracellular Ca2+ which induces an 
increment in the inward Na+ current, facilitated by the action of the Na+-Ca2+ exchanger. Delayed 
afterdepolarizations occur in digitalis toxicity, catecholamine overstimulation, ischemia, and 
reperfusion (Rosen 1994). 
3.3.3.2. Acute ischemia and infarction 
3.3.3.2.1. General 
Factors contributing to the generation of ventricular arrhythmias during acute ischemia include the 
size of the ischemic area, the presence of preexisting collaterals, the occurrence of a single 
prolonged period of ischemia versus successive occlusions and reperfusions, the presence of a prior 
myocardial infarction or myocardial hypertrophy, the heart rate, and the activity of the autonomic 
nervous system (Lown et al. 1969, Janse and Wit 1989). Ventricular arrhythmias appear within 
minutes following the start of the electrocardiographic signs of ischemia. Ventricular arrhythmias 
are also common when ischemia is relieved (reperfusion).  
3.3.3.2.2. Electrophysiological effects of acute ischemia 
Cells exposed to acute ischemia are depolarized within minutes. This is caused by extracellular 
accumulation of K+ due to partial inhibition of the Na+-K+ pump, intracellular K+ efflux, and 
changes in the activity of K+ channels, especially the ATP-sensitive K+ channel (Janse and Witt 
1989, Kline et al. 1992). Increases in intracellular concentrations Ca2+ and Na+ and accumulation of 
ischemia-produced metabolites further contribute to the depolarization (Janse and Witt 1989). 
During the first two minutes, however, a slight prolongation of the action potential occurs. This is 
followed by decreases in the amplitude and upstroke velocity of the action potential along with a 
concomitant shortening of it. 
Refractoriness (recovery of excitability) follows the action potential changes. First, an increase 
of refractoriness occurs, followed by a decrease. Importantly, refractoriness becomes dispersed. 
Unlike decreased refractoriness in the borderline zone, cells in the central ischemic zone remain 
non-excitable after full repolarization, and refractoriness will be prolonged (postrepolarization 
refractoriness). This dispersion results from a spatially inhomogenous rise in the extracellular K+
(Janse and Witt 1989).  
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3.3.3.2.3. Alterations in cellular magnesium distribution 
The elctrolyte changes in ventricular myocytes follow a characteristic time course during 
progressive ischemia. The intracellular free Mg2+ increases during the very early stages of ischemia. 
This transient phenomenon is probably due to a dissociation of Mg2+ from its complexes with ATP 
when energy production is compromised. After 1-2 hours of hypoxia, a loss of Mg2+ and K+ from
the cytoplasm without alteration in Na+ and Ca2+ occurs. These initial changes take place in the 
absence of cell injury (Murphy et al. 1989, Borchgrevink et al. 1989).  
Associated with the inception of cell injury at 3-5 hours of hypoxia, there is an additional release 
of K+ from the cytoplasm, and the cytoplasm begins to gain Na+, Ca2+, and chloride; these effects 
are probably due to inhibition of the sarcolemmal Na+-K+ pump and subsequent activation of the 
Na+-Ca2+ exchange mechanism together with increased membrane permeability (Walsh and Tormey 
1988, Thandroyen et al. 1992). Furthermore, a marked efflux of free and total Mg2+ out of the cell 
occurs. This is likely caused by a passive leakage of Mg2+ or through a Mg2+-Na+ transport system 
(White and Hartzell 1989). Because of the central role of free Mg2+ in the regulation of the function 
of K+ and Ca2+ channels, this reduction may further contribute to K+ efflux and Ca2+ influx (White 
and Hartzell 1989). Moreover, mitochondria start to accumulate Na+, chloride, and Ca2+, whereas 
Mg2+ and K+ are lost. (Walsh and Tormey 1988, Thandroyen et al. 1992). When the hypoxia is 
relieved, the electrolyte homeostasis in the subcellular compartments is partially restituted 
(Thandroyen et al. 1992). The intracellular concentration of Mg2+ is increased during reperfusion 
(Murphy et al. 1989). 
3.3.3.2.4. Characteristics and mechanisms of acute and subacute ischemic arrhythmias 
Complete occlusion of a coronary artery produces early ventricular arrhythmias in two phases in 
experimental studies. Initially (phase 1a) arrhythmias arise between 2 and 10 minutes after start of 
ischemia. Second phase (phase 1b) arrhythmias emerge 12 – 30 minutes of start of ischemia. The 
basic arrhythmogenic mechanisms in phase 1a involve inhomogenous conduction slowing with 
delayed recovery of excitability in the subepicardial myocardium leading to circus movement 
reentry within the ischemic myocardium. When multiple wavefronts propagate irregularly, 
degeneration into VF may occur (Janse and Witt 1989). Ventricular premature depolarizations 
might be caused by microreentry or EADs within the Purkinje fibers close to the ischemic cells and 
by injury currents induced by membrane potential differences between adjacent depolarized 
ischemic and healthy polarized cells. Recently, a mechanism called phase 2 reentry has been shown 
to trigger circus movement reentry (Lukas and Antzelevitch 1996). The mechanisms of phase 1b 
arrhythmias are largely unknown but they are apparently related to the release of catecholamines, 
which happens at that time (Janse and Witt 1989).  
Abrupt restoration of blood flow to the ischemic area (reperfusion) leads to a rapid recovery of 
the ischemia-induced electrophysiological abnormalities. Within the first seconds, action potential 
recovery may be markedly inhomogeneous; this facilitates the induction of reentrant tachycardias. 
The initial VPB triggering the tachycardia probably arises by a nonreentrant mechanism in the 
border between ischemic and nonischemic myocardium. Increased automaticity in partially 
depolarized Purkinje fibers is also involved (Janse and Witt 1989).  
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Delayed ventricular arrhythmias appear between 6 h and 3 days after AMI. The most probable 
mechanism for such late arrhythmias is abnormal automaticity originating from surviving 
subendocardial Purkinje fibers. Enhanced sympathetic activity may contribute here, as implicated 
by an increased sensitivity of Purkinje fibers to catecholamines. Triggered activity secondary to 
delayed afterdepolarizations probably underlies some of these arrhythmias (Janse and Witt 1989).  
Clinically, early bradyarrhythmias accompany about 30 % and VPBs 93 % of the patients with 
AMI. Sustained VTs and supventricular tachycardias (SVT) are uncommon (Pantridge et al. 1981). 
The incidence of VF is 5.5 - 19 %; VF occurs mostly within the first four hours after the onset of 
chest pain (Lown and Wolf 1971, Pantridge et al. 1981). VPBs preceding VF, so called warning 
ventricular arrhythmias, have been characterized (Lown and Wolf 1971). 
3.3.3.2.5. Determinants of ischemic arrhythmias 
Ischemia and size of infarction. Experimental data indicate that the extent of myocardial damage 
is related to the generation of ventricular arrhythmias in AMI (Lown et al. 1969). Clinically, the 
extent is expressed as the amount of released myocardial enzymes and left ventricular EF. Thus, 
creatine kinase MB isoenzyme activity is a powerful independent predictor of early occurrence of 
sustained monomorphic VT (Mont et al. 1996). While a low EF is a potent predictor of total 
mortality, it is a poor predictor of arrhythmic deaths (Hartikainen et al. 1996). Patency of the 
infarct-related artery determines strongly the electrical stability of the myocardium, as shown by 
Hohnloser and coworkers (1994a), who reported that among established prognostic parameters only 
occluded infarct artery occlusion predicted independently the occurrence of severe arrhythmias.  
Ischemia detection. Compared to conventional non-invasive methods to assess ischemia (Holter 
recording and electrocardiography) vectorcardiography (VCG) is more sensitive in detecting 
recurrent myocardial ischemia, especially if the ischemia resides in the lateral and inferoposterior 
regions of the left ventricle (Frank 1956, Chou 1986). Continuous dynamic computerized on-line 
VCG monitoring separates patients with unstable angina pectoris from those with AMI and 
identifies vessel patency in association with AMI (Lundin et al. 1992, Dellborg et al. 1995). 
Furthermore, VCG monitoring during the first 24 hours of hospitalization offers prognostic 
information in patients with unstable angina pectoris and AMI (Lundin et al. 1994, Lundin et al. 
1995).
Autonomic control of the heart. Ischemia, myocardial infarction, and reperfusion can cause 
profound functional changes in the autonomic innervation of the heart. It has been shown 
experimentally that impairment of cardiac neural function occurs within minutes after cessation of 
coronary blood flow and that this impairment is reversible only with rapid interventions (Zipes 
1990). It is well known clinically that acute inferoposterior myocardial ischemia provokes reflex 
bradycardia and hypotension, and anterior ischemia causes tachycardia and hypertension (Webb et 
al. 1972, Pantridge et al. 1981). Following this acute response, denervation of afferents and 
efferents produce inhibition of autonomic reflexes. The resultant attenuation in the sympathetic and 
parasympathetic responses is regarded as a functional rather than structural phenomenon, since 
responsiveness of the heart to various autonomic stimuli is preserved. Thus, the affected pathways 
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are probably prejunctional, related to ischemic changes in the axons, or there is an accumulation of 
metabolites in the myocardium (Zipes 1990). Finally, denervation supersensitivity can make 
postjunctional cells hyperreactive to various physiologic and pharmacologic challenges (Zipes 
1990). The overall reaction to ischemia is probabaly a mixture of inhibiting and activating 
responses, which is strongly dependent on the anatomical localization, transmurality, and degree of 
mechanosensitive and chemosensitive irritation (Zipes 1990). With respect to refractoriness and 
conduction, the resultant electrophysiological milieu becomes inhomogenous and, thus, vulnerable 
to induction of ventricular arrhythmias (Han et al. 1964). 
In clinical studies, the change in the autonomic balance is determined by heart rate variability 
(HRV) and baroreflex sensitivity (BRS). HRV is measured from the 24 h ambulatory ECG 
recording. Of the methods based on linear dynamics, both time-domain and frequency-domain 
calculations have been used (Task Force of the European Society of cardiology and the North 
American Society of Pacing and Electrophysiology 1996). Recently, methods based on nonlinear 
dynamics have been introduced (Huikuri et al. 1999). Baroreflex sensitivity, a sympatho-vagal 
reflex following an abrupt increase in blood pressure, can be determined by phenylephrine injection 
and by the Valsalva maneuver (La Rovere et al. 1988, Airaksinen et al. 1993). 
AMI is associated with depressed HRV, and this may be established both by time-domain and 
frequency-domain techniques. This suppression develops early, within the first day after an AMI. It 
is maintained throughout the early period of convalescence, and may still be demonstrated 12 
months after the incident (Kleiger et al. 1987, Bigger et al. 1991, Casolo et al. 1992, Singh et al. 
1996, Lombardi et al. 1996). A pattern of sympathovagal disturbance characterized by reduced 
vagal and increased sympathetic activation has been demonstrated in connection with myocardial 
ischemia (Lombardi et al. 1996). The degree of attenuation of HRV has been associated, although 
not consistently, with infarct site and size, with the preservation of coronary blood flow, EF, heart 
rate, and the age of the patient (Casolo et al. 1992, Singh et al. 1996, Lombardi et al. 1996, Pitzalis 
et al. 1998). 
Depressed BRS accompanies AMI already after the first week of the acute incident. Thereafter, 
BRS increases and at 3 months it does not differ from healthy subjects (Schwartz et al. 1988). BRS 
correlates variably with localization and extent of AMI, age of patients, heart rate, mean blood 
pressure, severity of coronary artery disease, fibrinolytic therapy, infarct-related artery patency, and 
neurohormonal activation (Schwartz et al. 1988, La Rovere et al. 1988, Odemuyiwa et al. 1993, 
Hartikainen et al. 1995, Mortara et al. 1996, Mortara et al. 1997, La Rovere et al. 1998). 
According to retrospective and prospective data, both blunted reflex (BRS) and tonic (HRV) 
vagal reactions after myocardial infarction have been associated with the appearance of 
postinfarction ventricular arrhythmias and arrhythmic deaths (Kleiger et al. 1987, La Rovere et al. 
1988, Farrel et al. 1991, Bigger et al. 1992, Casolo et al. 1992, Perkiömäki et al. 1997, La Rovere et 
al. 1998). Both are powerful independent estimators of survival, but BRS differentiates more 
accurately than HRV the patients prone to sustained VT, VF, or cardiac death (Farrel et al. 1992, 
Hohnloser et al. 1994b, La Rovere et al. 1998). This implies that these variables measure vagal 
regulation of the heart from different aspects. 
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Abnormal repolarization. While the QT interval is not prolonged until the third or fourth day 
after AMI, QT dispersion (maximal QT duration minus minimal QT duration on a standard 12 lead 
ECG) is increased already on admission to the coronary care unit (Doroghazi and Childers 1977, 
Mirvis 1985, Higham et al. 1995). The increase is greatest during the early hours, persists for the 
first three days, and recurs within four weeks in uncomplicated recovery (Glancy et al. 1995, 
Higham et al. 1995). QT dispersion is more pronounced in anterior than in inferior or lateral 
infarctions, and occlusion in the left anterior descending coronary artery produces more prominent 
dispersion than occlusions of other coronary branches (Moreno et al. 1994). The magnitude of QT 
dispersion is inversely related to the perfusion grade of the infarct-related coronary artery (Moreno 
et al. 1994). QT dispersion is not related to QT duration or heart rate directly, and actions that 
prolong QT duration do not implicitly increase the QT dispersion (Cui et al. 1994). 
Spatial QT dispersion is a known marker of regional inhomogeneity of ventricular repolarization. 
Dispersion is attributed to differences in the duration of local myocardial cell action potentials. In 
ischemia, repolarization is modified by the viability of the cells in the border zone between non-
ischemic and ischemic regions (Schneider et al. 1997). Furthermore, recent data suggest that there 
are inherent differences in the responsiveness of myocardial cells to pathophysiologic stimuli, 
depending on their location in the myocardium (epicardial, endocardial, M-cells) (Kuo et al. 1985, 
Day et al. 1990, Kurz et al. 1994, Pye et al. 1994, Schneider et al. 1997, Antzelevitch et al. 1998). 
Inhomogeneity in recovery times (refractoriness) forms the basis for re-entrant arrhythmia 
mechanisms (see also section 3.3.3.1) (Janse and Wit 1989). 
The electrocardiographic QT duration measured at discharge of patients hospitalized for an AMI 
identifies variably individuals at increased risk for death (Ahnve et al. 1984, Pohjola-Sintonen et al. 
1986). Among patients who survived an AMI, excessively dispersed repolarization detected at 
discharge or thereafter is prognostic of later life-threatening ventricular arrhythmias or sudden death 
in many studies (Zareba et al. 1994, Pye et al. 1994). However, conflicting results have recently 
been reported in prospective series of infarct survivors (Zabel et al. 1998). Nevertheless, the very 
early QT dispersion measured within the first 3 days predicts the risk of the patients to develop in-
hospital VF (van de Loo et al. 1994, Higham et al. 1995) but does not provide information on long-
term prognosis (Glancy et al. 1995). Furthermore, dynamic changes in repolarization, peaks of very 
long corrected QT intervals or morphological alternations within the T wave identify patients prone 
to VT and who then have a poor prognosis (Marti et al. 1992, Rosenbaum et al. 1994). Whether the 
vulnerability to ventricular arrhythmias in patients with AMI would be attenuated through 
interventions targeted specifically at QT dispersion shortening is not known. 
Summary of determinats of arrhythmias. According to the prevailing electrophysiological 
thinking, the generation of arrhythmias is a result of the interplay between the underlying anatomic 
structure (substrate), its functional modulators, and final triggers. Induction of VT in programmed 
electrical stimulation, the appearance of late potentials in signal-averaged electrocardiograms, and 
increased ventricular ectopic activity indicate the presence of an anatomic arrhythmia structure. 
Increased variability in repolarization is mainly regarded as a manifestation of a reentrant 
arrhythmia mechanism and, thus, a marker of a fixed ventricular arrhythmia substrate, presenting 
with VF or VT. Altered cardiac autonomic regulation is considered to be a modulating or priming 
factor with regard to the induction of ventricular arrhythmias. However, various risk stratification 
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parameters have characterized the electrophysiological arrhythmia mechanisms inaccurately in 
prognostic studies. 
3.3.3.2.6. Significance of ventricular arrhythmias in acute myocardial infarction 
Evidence has accumulated that ventricular arrhythmias reduce overall survival of the patients after 
AMI (Bigger et al. 1981, Statters et al. 1996). Sustained monomorphic VT appears infrequently 
during the first 48 h of infarction, in 1.9 %, but when present, it strongly predicts a poor in-hospital 
outcome and late prognosis (Mont et al. 1996). Among survivors of AMI, the frequency of PVBs 
and their appearance in pairs or runs, and appearing in a R-on-T manner on resting ECG are all 
independent predictors of total and sudden death (The Coronary Drug Project Research Group 
1973, Ruberman et al. 1977). An increased frequency of VPBs and ventricular repetitive forms 
(couplets or nonsustained VT) at predischarge 24 h ambulatory ECG recording have predicted an 
adverse arrhythmic outcome also during the fibrinolytic era (Farrel et al. 1991, Statters et al. 1996, 
Maggioni et al. 1993). 
3.3.3.3. Cardiac surgery 
3.3.3.3.1. Atrial fibrillation  
Incidence of postoperative atrial fibrillation. AF appears in 10 to 50 % of patients undergoing 
CABG (Lauer et al. 1989, Rubin et al. 1987, Leitch et al. 1990, Andrews et al. 1991, Frost et al. 
1992, Creswell et al. 1993, Aranki et al. 1996, Mathew et al. 1996). The incidence increases to 92 
% if CABG is combined with valvular reconstructions (Creswell et al. 1993).  
Substrate for postoperative atrial fibrillation. AF is considered to be a reentrant arrhythmia 
due to multiple continuous intraatrial microreentrant circuits (the multiple wavelet hypothesis) 
(Moe 1962, Allessie et al. 1990). Electrophysiologically, it is characterized by shortening of the 
atrial effective refractory period, inhomogeneity of refractoriness, and delayed intraatrial 
conduction. (Cox 1993, Allessie et al. 1995). Cox (1993) has demonstrated that disruption of the 
normal gradual change in refractoriness between adjacent regions (nonuniform dispersion of 
refractoriness) and prolongation of intraatrial conduction make the atria vulnerable to the 
development of AF postoperatively. According to this hypothesis, the preexisting (i.e., 
preoperative) vulnerability forms the basis for the unique stimuli of cardiac operations to trigger AF 
(Sato et al. 1992, Cox 1993). The duration of the P-wave, a noninvasive marker of intraatrial 
conduction properties, predicts sensitively but not specifically postoperative atrial arrhythmias 
(Buxton and Josephson 1981, Steinberg et al. 1993, Zaman et al. 1997). A prolongation of the 
filtered P-wave duration alone or in combination with a lowered root-mean-square voltage for the 
last 20 msec of the P-wave (atrial late potential) in signal averaged P-wave measurement predict the 
occurrence of paroxysmal AF (Fukunami et al. 1991, Guidera and Steinberg 1993, Zaman et al. 
2000). Prolonged atrial activation may represent a marker of the arrhythmia substrate, while some 
extra triggers are needed for the initiation and maintenance of AF. This concept was demonstrated 
by Zaman and coworkers (2000), who found that a signal averaged P-wave duration >155 ms 
combined with advanced age and male gender was a powerful variable in stratifying patients at risk 
for postoperative AF. 
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The electrophysiological characteristics of postoperative AF have been described. Wells and 
coworkers (1978) found four types of AF classified by bipolar intraatrial electrograms. Type I has 
discrete atrial complexes and an isoelectric baseline. Type II comprises discrete complexes 
interpolated within a perturbed nonisoelectric baseline. Type III consists of totally fragmented 
nondiscrete complexes. Type IV incorporates type II with the other types. Patients who will develop 
AF after a cardiac operation may also be identified by splitting of the atrial electrogram or induction 
of AF in atrial stimulation performed before the initiation of cardioplegia (Capucci et al. 1987, 
Lowe et al. 1991). At the atrial cellular level, there are abnormalities in phase four depolarization, 
conduction velocities and transmembrane action potentials (Bush et al. 1971). While corresponding 
changes have been induced experimentally by enlarging the atria, clinical data are inconsistent 
concerning the role of atrial size in provoking postoperative AF (Boyden and Hoffman 1981, Frost 
et al. 1992). 
AF itself leads to a reversible shortening of atrial refractoriness, a phenomenon called atrial 
electric remodeling (Wijffels et al. 1995). Electrophysiologically, this is identified by shortening of 
the atrial action potential duration and by a decrease in its adaptation to heart rate (Yue et al. 1997). 
Reductions in the transient outward K+ current (Ito) and L-type Ca2+ current (ICa) densities secondary 
to myocyte Ca2+ overload are the underlying determinants (Yue et al. 1997, Van Wagoner et al. 
1999). Patients who develop postoperative AF have an increased Ca2+ current density. This 
contradicting mechanism is probably explained by increased catecholamine stimulation, 
characteristic for the postoperative state, which is known to increase Ca2+ influx through L-type 
Ca2+ channels (Van Wagoner et al. 1999). While verapamil has reduced the electrical remodeling 
and the persistence of AF (Tieleman et al. 1997), its efficacy in preventing postoperative AF is 
limited (Andrews et al. 1991). 
Autonomic control of heart. Both sympathetic and parasympathetic activation have been 
claimed to trigger AF (Coumel 1992). Although the postoperative period is characterized by 
increased noradrenaline excretion and although the noradrenaline levels are higher in patients who 
experience AF, there is no uniform pattern of autonomic derangement that is related to the 
development of postoperative AF (Kalman et al. 1992, Kalman et al. 1995, Hogue et al. 1998). Low 
vagal tone could predict the appearance of postoperative AF (Frost et al. 1995). Non-linear but not 
linear estimates of HRV and increased heart rate during the preceding hour of the onset of an AF 
episode have associated with AF (Hogue et al. 1998). 
-blocker withdrawal. Patients in whom the preoperative -blocker treatment has been 
discontinued prior to the cardiac operation and not reinstituted afterwards, experience more often 
AF than patient with postoperative -blocker treatment (Salazar et al. 1979, Zaman et al. 1997). 
Furthermore, several randomized trials have demonstrated that postoperative treatment with 
different -adrenergic blocking agents reduces the incidence of AF (Fuller et al. 1989, Andrews et 
al. 1991, Kowey et al. 1992). Pooled data of these prophylactic studies demonstrate a 72 % 
reduction in the incidence of postoperative AF (Andrews et al. 1991). Arrhythmogenity inherent to 
catecholamine stimulation, postoperative catecholamine oversecretion, and upregulation of cardiac 
-adrenergic receptors along with increased sensitivity to catecholamines have been proposed as the 
contributing mechanisms (Boudalas et al. 1977, Aarons et al. 1980, Lauer et al. 1989, Kalman et al. 
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1992).
Atrial injury. Atrial protection during the cardioplegic arrest of open-heart surgery may be 
incomplete (Mullen et al. 1987, Cox 1993). The extent of the consequent atrial ischemic injury 
predicts the appearance of postoperative AF; this may be demonstrated by creatine kinase MB 
isoenzyme release or by atrial electrical activity during the arrest and is associated witht he aortic 
cross clamp time (Tchervenkov et al. 1983, Mullen et al. 1987, Creswell et al. 1993). 
Extracorporeal circulation as such is probably not a cause for postoperative AF (Saatvedt et al. 
1999).
The cold crystalloid antegrade cardioplegic technique produces more supraventricular 
arrhythmias than warm blood cardioplegia in some studies (Mullen et al. 1987, Gundry et al. 1989), 
while in another study there was no difference (Lajos et al. 1993). Experimental data have 
demonstrated that augmented atrial hypothermia, designed to intensify atrial protection, counteracts 
the ischemia-induced electrophysiological changes. Yet it has no influence on the inducibility of AF 
(Chen et al. 1988, Sato et al. 1992). 
Hypomagnesemia and magnesium depletion. Hypomagnesemia is associated with the 
occurrence of postoperative supraventricular arrhytmias. In the series of England and coworkers 
(1992), patients with postoperative normomagnesemia had a significantly lower frequency of newly 
onset supraventricular arrhythmias (17%) than hypomagnesemic patients (37%). In the series of 
Zaman and coworkers (1997), patients with postoperative AF had a lower serum Mg2+
concentration on the first postoperative day than patients without AF, and the mean serum Mg2+ 
concentration as a group (0.62 mmol/l) was below the lower reference limit for serum Mg2+ (0.7 
mmol/l). By multivariate analysis, the serum Mg2+ concentration on the first postoperative day was 
an independent predictor of AF but it alone had a low specificity and low positive predictive value 
(Zaman et al. 1997). A combination of a P-wave duration > 155 ms on signal averaged ECG and a 
serum Mg2+ concentration on the first postoperative day of < 0.7 mmol/l has a sensitivity of 75 % 
and specificity of 80 % for predicting AF (Zaman et al. 1997). Reinhart and coworkers (1991) 
studied the concentration of Mg2+ in the myocardium of patients undergoing cardiac surgery, and 
found a significantly reduced mean Mg2+ concentration in the right atrial appendage of patients with 
a history of recent postoperative cardiac arrhythmias requiring treatment, including AF.  
Risk factors. Age is one of the most consistent independent risk factor for the occurrence of AF 
after cardiac surgery (Lauer et al. 1989, Fuller et al. 1989, Leitch et al. 1990, Creswell et al. 1993, 
Zaman et al. 1997, Parikka et al. 1998). The influence of increasing age is more or less linear 
(Aranki et al. 1996), or it may be sigmoidal with quite a steep elevation in the incidence between 45 
and 85 years of age (Creswell et al. 1993). In both studies, the incidence exceeds 50 % among 
patients above 80 years of age (Creswell et al. 1993, Aranki et al. 1996).  
Other preoperative predictors of postoperative AF are male gender (Aranki et al. 1996, Mathew 
et al. 1996, Zaman et al. 2000), hypertension (Aranki et al. 1996), a history of AF (Mathew et al. 
1996), congestive heart failure (Mathew et al. 1996) or rheumatic heart disease (Creswell et al. 
1993), prior use of angiotensin converting enzyme inhibitors (Zaman et al. 1997) and digoxin 
(Creswell et al. 1993), chronic airway obstruction (Leitch et al. 1990, Creswell et al. 1993), chronic 
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renal failure (Leitch et al. 1990), severe right coronary artery stenosis (Mendes et al. 1995), left 
ventricular end-diastolic pressure > 20 mmHg (Hashimoto et al. 1991), increased number of atrial 
premature beats (Frost et al. 1996), and the preoperative heart volume (Parikka et al. 1998). 
Intraoperative factors include the need for intraoperative intra-aortic balloon pump treatment 
(Aranki et al. 1996), precardiopulmonary bypass heart rate of more than 100 beats per minute 
(Mathew et al. 1996), pulmonary vein venting (Mathew et al. 1996), bicaval venous cannulation 
(Mathew et al. 1996), and increased cross-clamp time (Creswell et al. 1993, Mathew et al. 1996). 
Postoperative pneumonia (Aranki et al. 1996), ventilation for more than 24 hours (Aranki et al. 
1996), pericardial effusion (Angelini et al. 1987), and return to the intensive care unit (Aranki et al. 
1996) are also associated with postoperative AF. On the other hand, Rubin and coworkers (1987) 
did not identify a single predictor. 
3.3.3.3.2. Ventricular arrhythmias 
Incidence of postoperative ventricular arrhythmias. Ventricular arrhythmias occur in 5 to 78 % 
of patients after cardiac surgery (Michelson et al. 1979, Rubin et al. 1985, Ferraris et al. 1991, 
Chiolero et al. 1991). The incidence is highest during the first three postoperative days peaking on 
the very first (Ferraris et al. 1991) but it does not seem to decrease very much toward hospital 
discharge (Rubin et al. 1985). Newly onset sustained VTs appear in 0.7 - 1 % and VF in 0.5 % of 
the patient (Kron et al. 1984, Topol et al. 1986). The occurrence of postoperative ventricular 
arrhythmias depends on the registration period, the detection method, the criteria for arrhythmias 
and the study population. Not surprisingly, prolonged detection periods and the most sensitivity 
method, Holter monitoring, have yielded highest incidence figures (Michelson et al. 1979, Rubin et 
al. 1985, Ferraris et al. 1991, Chiolero et al. 1991).  
Substrate and risk factors. A pre-existing structural arrhythmia substrate is a major 
determinant of severe postoperative ventricular arrhythmias, despite successful revascularization 
(Huikuri et al. 1985, Kelly et al. 1990). Among patients with moderately depressed left ventricular 
function (EF >35 %), Ferraris and coworker (1991) discovered advanced age and preoperative use 
of Ca2+ antagonists as independent predictors of the development of serious ventricular arrhythmias. 
Casthely and coworkers (1994) demonstrated that patients with hypokalemia were more prone to 
postoperative ventricular arrhythmias than normokalemic patients. However, Rubin and coworkers 
(1985) did not detect predictors of postoperative complex ventricular arrhythmias in patients with 
normal left ventricular function. The long-term outcome of patients with postoperative arrhythmias 
is strongly dependent on the type of the arrhythmia and ventricular function (Rubin et al. 1985, 
Kelly et al. 1990).  
Hypomagnesemia. Despite the demonstration that patients are clearly hypomagnesemic 
postoperatively, a definitive connection between hypomagnesemia and the occurrence of ventricular 
arrhythmias has been reported only infrequently. England and coworkers (1992) reported that 
patients with total and ionized hypomagnesemia had more ventricular arrhythmias than 
normomagnesemic subjects. However, the coexistence of hypokalemia was significantly 
accentuated in patients with lowered Mg2+ levels (52 % vs 22 %, respectively). 
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3.3.3.4. Early afterdepolarizations-induced arrhythmias 
TdP is a unique type of polymorphic VT, characterized by a phasic variation in the polarity and 
amplitude of the QRS complexes forming a spinning movement around the isoelectric baseline. 
Usually it is repetitive and self-terminating but it may lead to VF (Dessertenne 1966, Surawicz 
1989). TdP is typically initiated by a sequential appearance of long and short QRS complex 
intervals, caused by PVBs (R-on-T phenomenon) (Surawicz 1989, Jackman et al. 1988). By 
definition, a prerequisite for the generation of TdP is prolonged repolarization, represented 
electrocardiographically as QT interval prolongation (Surawicz 1989). QT prolongation and 
consequent TdP polymorphic VT can be congenital or acquired (Jackman et al. 1988). Acquired QT 
prolongation may result from an idiosyncratic reaction to or from an overdose of antiarrhythmic 
(Vaughan Williams classes IA and III), antipsychotic (phenothiazides), antidepressant (tricyclic), or 
antihistamine drugs (Viskin 1999). In addition, metabolic disorders (hypothyroidism, anorexia 
nervosa, treatment with liquid-protein diet), electrolyte disturbances (hypokalemia, 
hypomagnesemia), poisoning with organophosphorus compounds, cerebrovascular incidents 
(especially subarachnoid hemorrhage), and marked bradycardia can cause acquired long QT 
syndrome (Viskin 1999). Prolonged repolarization in congenital forms of the long QT syndrome is 
caused by a genetic disorder with mutations in the genes encoding the production of the protein 
structures of some K+ and Na+ channels (Viskin 1999). 
There are two main hypotheses on the mechanisms of the generation of TdP polymorphic VT: 
EADs giving rise to triggered activity, and an inhomogenous repolarization (dispersion of 
repolarization) setting basis for reentry (Surawicz 1989, Verduyn et al. 1997). This dispersion in the 
action potential duration (repolarization) may appear within the ventricle or between the ventricles 
(Habbab and El-Sherif 1990, Verduyn et al. 1997). These mechanisms are not mutually exclusive, 
since if EADs and action potential prolongation originate regionally, dispersion will be increased. 
Similarly, the ectopic impulse following the initial triggered depolarization could perpetuate as a 
reentrant circuit if repolarization is non-uniform. The characteristic configuration of TdP is 
incompletely understood. The initiating beat is probably triggered from an EAD in the Purkinje 
network. Thereafter, competing foci (D’Alnoncourt et al. 1982), spiral wave reentry (El-Sherif et al. 
1996), and phase two reentry (Antzelevitch and Sicouri 1994) would enable perpetuation of the 
arrhythmia.  
In cellular electrophysiology, EADs and prolonged repolarization are provoked when inward 
depolarizing currents exceed the outward repolarizing currents during phases 2 and 3 of the cardiac 
action potential. Consequently, EADs in ventricular muscle cells and Purkinje fibers can be induced 
by decreasing the K+ conductance by blocking K+ currents, including Ito, IKr, IKs and K1. In vitro and 
in vivo this is elicited by low K+ superfusion, total AV conduction block, pacing modes utilizing 
long cycles or abrupt cycle length changes, or with direct blockers of K+ conductance, such as 
quinidine, sotalol (blockers of multiple currents, predominantly IKr), cesium (blocker of IK1), d-
sotalol and dofetilide (specific blockers of IKr) (Levine et al. 1985, Bailie et al. 1988, Kaseda et al. 
1989, Vos et al. 1995). EADs are most readily induced in myocytes where intrinsic prolongation of 
the action potential occurs, the M-cells (Antzelevitch and Sicouri 1994). However, following these 
experimental maneuvers, not all the generated arrhythmias are of the TdT type – sustained 
monomorphic VT, VF, and sinus arrest are also created (Bailie et al. 1988, Kaseda et al. 1989). 
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3.3.4. Hypomagnesemia, magnesium depletion and associated cardiac arrhythmias 
Arrhythmias in acute myocardial infarction. The incidence of SVT and AF is significantly 
higher in patients with a serum Mg2+ concentration below 0.7 mmol/l than above it during the first 
24 hours following an AMI (Dyckner 1980). The same serum level identifies patients at risk of 
developing SVT and AF even without myocardial injury (Dyckner 1980). The incidence of AF 
during the hospital course is, however, independent of the serum Mg2+ concentration on admission 
to the emergency department (Madias et al. 1996). 
Although hypomagnesemia is common in the early phase of AMI its association with the 
incidence of ventricular arrhythmias has not been established conclusively. Experimentally, dogs 
made Mg2+ deficient by a diet devoid of magnesium were more prone to VF after coronary 
occlusion than dogs on a normal diet (Chang et al. 1985). In a series of consecutive patients 
admitted to the coronary care unit, those with AMI and hypomagnesemia had more serious 
ventricular ectopics (multifocal, >5 ectopics per minute, coupled ectopics, or R-on-T phenomen), 
VT and VF on admission compared to those with normomagnesemia. In patients without AMI, 
hypomagnesemia does not correlate with the appearance of ventricular arrhythmias (Dyckner 1980). 
Also during the first 24 hours of observation, hypomagnesemic AMI patients tend to have more 
ventricular arrhythmias than normomagnesemic patients. The incidence of ventricular arrhythmias 
could not be accounted for the extent of the myocardial injury. In agreement with these results, 
Kafka and coworkers (1987) reported a weak link between hypomagnesemia and the occurrence of 
major ventricular arrhythmias: the incidence was 77 % in the hypomagnesemic versus 50 % in the 
normomagnesemic subjects. In this study major ventricular arrhythmias were defined as VF, VT – 
more than three VPBs in sequence, or complex VPBs – more than six VPBs per minute, R-on-T 
phenomenon, couplets or triplets. 
Despite the documentation of a clear fall in serum Mg2+ level following AMI, Abraham and 
coworkers (1986) did not find an association between hypomagnesemia and the occurrence of 
tachyarrhythmias during the first 5 days after AMI. In the same study, a high lymphocyte K+
concentration separately and especially connected with a low Mg2+ concentration predicted the 
appearance of tachycardias. In contrast, a high lymphocyte Mg2+ concentration tended to prevent 
tachyarrhythmias associated with elevated lymphocyte K+ concentration. The authors interpreted 
these findings by claiming that the lymphocyte cation concentrations reflect myocardial interstitial 
concentrations, and that a high interstitial Mg2+ level protects against increased excitability caused 
by elevated interstitial K+ concentrations (Abraham et al. 1986). Ryzen and coworkers (1986), while 
showing a significantly lowered mononuclear cell Mg2+ concentration in coronary care unit patients 
measured within 24 hours of admission, could not find an excessive reduction in the number of 
patients who experienced any kind of arrhythmia, neither in the whole patient population nor among 
those with AMI. In a prospective study by Madias and coworkers (1996), 26 % of the patients were 
hypomagnesemic on admission but compared with the normomagnesemic patients, they did not 
experience more VT or VF. Patients with inducible monomorphic VT after AMI do not have  
reduced tissue Mg2+ levels (Haigney et al. 1997). 
TdP ventricular tachycardia. Although hypomagnesemia and Mg2+ depletion are commonly 
listed as causes of TdP, evidence supporting this relationship comes from only a few case reports 
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(Loeb et al. 1968, Levine et al. 1982, Topol and Lerman 1983, Ramee et al. 1985). While 
hypomagnesemia or Mg2+ deficiency and prolongation of the electrocardiographic QT interval were 
apparent in all the reported cases, other factors known to cause TdP (hypokalemia, bradycardia) 
were also present in many of them (Loeb et al. 1968, Levine et al. 1982, Ramee et al. 1985). 
Other arrhythmias. An association between hypomagnesemia, Mg2+ depletion and arrhythmias 
due to digitalis toxicity has been reported frequently (Kim et al. 1961, Seller et al. 1970, Seller 
1971, Beller et al. 1974). Typical arrhythmias caused by digitalis intoxication have been induced in 
hypomagnesemic patients who have had normal serum levels of digoxin (Seller 1971, Tackett and 
Holl 1981, Cohen and Kitzes 1983). The sensitivity of the myocardium to digitalis during Mg2+
depletion probably arises from inhibition of the Na+-K+ pump (Ferrier 1977, Roden 1989) and from 
increased accumulation of digoxin in the myocardium (Goldman et al. 1971).  
In a consecutive series of 45 patients with symptomatic newly onset AF, 20 % were found to be 
hypomagnesemic (DeCarli et al. 1986). An association has been proposed between 
hypomagnesemia and the occurrence of multifocal atrial tachycardia (Strickberger et al. 1988). 
Hypomagnesemic patients with heart failure experience more ventricular arrhythmias than 
normomagnesemic patients (Gottlieb et al. 1990, Eichhorn et al. 1993, Ceremuynski et al. 2000). 
However, in the series of Ralston and coworkers (1989), serum or intracellular Mg2+ concentrations 
were not related with the prevalence of serious ventricular arrhythmias detected by ambulatory 
recordings within one week of the measurement of the Mg2+ concentration. 
In the Framingham Heart Study, the prevalence of complex ventricular arrhythmias (VPBs 
>30/hour, multiform, or repetitive) detected on a short-term ambulatory Holter recording was 
inversely associated with serum Mg2+ levels in patients with no apparent structural heart disease. 
This finding was independent of age, sex, smoking, coffee and alcohol consumption, diuretic use, 
systolic blood pressure and left ventricular mass (Tsuji et al. 1994).  
3.3.5. Antiarrhythmic effects of intravenously administerd magnesium 
3.3.5.1. General  
In both isolated and intact animal hearts, a direct depressing effect on the sinus node, and a decrease 
in the AV (PR interval) and intraventricular conduction (QRS duration) velocities has been 
observed at supraphysiologic Mg2+ concentrations (van Dellen and Miller 1938, Smith et al. 1939, 
Grantham et al. 1960, Surawicz et al. 1961). Experimental hypocalcemia causes  sinus heart rate 
slowing and PR interval prolongation which are  intensified by Mg2+ excess and the QT interval 
lengthening is inhibited (Surawicz et al. 1961). 
In patients with normal cardiac conduction systems and without apparent heart disease, Mg2+
infusion producing a twofold steady-state increase in the serum level causes a significant 
prolongation of the PR interval (Kulick et al. 1988). The QRS, QT or corrected QT (Bazett formula) 
intervals are not affected but an early subtle and transient increase in heart rate does take place. 
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These changes are related to significant prolongations in the atrio-His interval and in the sinoatrial 
conduction time as shown by electrophysiologic stimulation technique. Furthermore, the antegrade 
AV nodal refractory period is significantly increased. The infusion has no effect on distal AV 
conduction, retrograde conduction velocity, ventricular or atrial refractoriness, sinus node recovery 
time, or on the cycle length of the AV nodal Wenckebach conduction block (Kulick et al. 1988). 
Adding to these observations, a 2.5-fold steady-state increase in serum Mg2+ concentration prolongs 
the sinus node recovery time, cycle length of the AV nodal Wenckebach conduction block, and 
QRS duration during rapid ventricular pacing in patients with cardiomyopathy and intraventricular 
conduction delays (DiCarlo et al. 1986). 
3.3.5.2. Effects in acute ischemia 
Experimental arrhythmias. The ischemia-induced elevation in the extracellular K+ concentration 
entails profound changes in the ventricular action potential. The resultant fall in the rapid upstroke 
of the action potential, decrease in the conduction velocity, and lowering of the resting membrane 
potential can be eliminated or significantly reduced by increasing the extracellular Mg2+
concentration (Kraft et al. 1980, Ponce Zumino et al. 1997). In the original experimental model 
using coronary artery occlusion-induced AMI, Harris and coworkers (1953) showed a 60 % success 
in abolishing the ensuing VTs. In experimental regional ischemia and reperfusion models, the 
occurrence of VPBs, VT and VF is less frequent at increased extracellular Mg2+ concentrations, 
provided that Mg2+ is administered before the reflow is induced (Ponce Zumino et al. 1997). 
Concordantly, intracoronary administration of Mg2+ concomitantly with reperfusion leads to 
improved postischemic recovery of metabolism and function, and to a significantly lower incidence 
of VF (Borchgrevink et al. 1989, Herzog et al. 1995). Furthermore, Mg2+ decreases catecholamine-
induced ventricular arrhythmias in a model of spontaneously beating cultured myocytes (Zdanow icz 
and Barletta 1991). These observations suggest that Mg2+ could suppress the Ca2+-induced non-
reentrant ventricular arrhythmias by preventing cytosolic Ca2+-oscillations during ischemia and 
reperfusion (Zdanowicz and Barletta 1991, Ponce Zumino et al. 1997).  
Clinical arrhythmias. Studies performed in the acute phase of AMI have revealed that the 
incidence of early ventricular arrhythmias is often lower in subjects treated with Mg2+ than in 
subjects who have not received Mg2+ (Morton et al. 1984, Smith et al. 1986, Ceremuynski et al. 
1989, Bertschat et al. 1989, Woods et al. 1992, ISIS-4 Collaborative Group 1995, Shechter et al. 
1995). Furthermore, the overall arrhythmicity decreases (Rasmussen et al. 1987, Abraham et al. 
1987, Shechter et al. 1990, Singh et al. 1990). Feldstedt and coworkers (1991) did not, on the other 
hand, detect any beneficial effect on ventricular arrhythmias but, instead, demonstrated an increased 
incidence of bradyarrhythmias in patients who were treated with Mg2+. Pooled data of the small-
scale studies published before 1992 demonstrated a clear reduction in the incidence of ventricular 
arrhythmias in AMI patients who received Mg2+ (Horner 1992). The reduction of ventricular 
arrhythmias is apparently not related to the timing of the Mg2+ infusion. These results may be a 
reflection of insufficiencies in statistical power, different Mg2+ dosage, varying time from onset of 
symptoms to starting the treatment, variable arrhythmia detection methods and nonstandard use of 
fibrinolytic therapy  – these circumstances have made it impossible to draw reliable conclusions 
about the suppressive mechanisms of Mg2+ supplementation. Furthermore, the arrhythmia reduction 
has only indirectly affected survival in respective studies, because the most potent arrhythmic 
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determinants of survival, i.e., VF and sustained VT, have been relatively infrequent in these studies 
with only small numbers of patients.  
Other effects. Experimental evidence has accumulated demonstrating that Mg2+ administration 
might reduce the size of the myocardial injury. In studies utilizing a single coronary artery 
ischemia-reperfusion model, Herzog and coworkers (1995) showed that intracoronary infusion of 
Mg2+ just at the onset of reperfusion results in a significantly reduced size of the infarct in pigs. If 
Mg2+ is delivered after one hour of reperfusion, this reduction is not achieved. If the administration 
of Mg2+ is started already during the occlusion phase and continued at reperfusion a similar 
reduction in the area of evolving necrosis (30 – 60 %) is achieved (Christensen et al. 1995, Barros et 
al. 1995). Furthermore, Leor and Kloner (1995) showed that Mg2+ infusion started before coronary 
occlusion results in a significantly diminished area of necrosis in rats exposed to early, but not to 
delayed reopening of the artery. Clinically, magnesium administration reduces ischemia in patients 
with unstable angina (Redwood et al. 1997). 
The mechanisms of infarct size limition are incompletely understood. Preservation of energy 
production or normalization of the transmembrane electrochemical gradients with a reduction in the 
intracellular Ca2+ overload may be directly involved (Hearse et al. 1978, Woods 1991, du Toit and 
Opie 1992). However, in contrast to the theory of direct cell protection cell death could not be 
prevented in isolated rat cardiac cells exposed to metabolic deprivation or hypoxia and 
reoxygenation, nor could the functional recovery of the cells be promoted by raised extracellular 
Mg2+ (Gallagher and Allshire 2000). The following indirect mechanisms of infarct size limitation 
may be involved: slowing of the heart rate and decreased mean arterial blood pressure (Leor and 
Kloner 1995), inhibition of platelet aggregation (Adams and Mitchell 1979, Hwang et al. 1992, Atar 
et al. 1994), promotion of coronary artery flow (Vigorito et al. 1991), coronary and peripheral 
arterial vasodilatation (Vigorito et al. 1991, Kimura et al. 1989), attenuation of production of free 
radicals and reperfusion injury (Garcia et al. 1998), and improvement of endothelial function 
(Shechter et al. 2000). Furthermore, postischemic myocardial dysfunction (stunning) is attenuated 
(Dunnet and Nayler 1978, du Toit and Opie 1992, Atar et al. 1994). 
Although experimental data are consistent, results from clinical studies have not been as 
unambiguous. A meta-analysis of early small trials ended in the conlusion that mortality is reduced, 
leaving, however, the mechanisms unclear (Teo et al. 1991). The incidence of heart failure or death 
from heart failure, which are clinical approximations of infarct size, has been reduced in some 
studies, but in the largest of them, ISIS-4, the incidence of heart failure was even higher among 
Mg2+ treated subjects (ISIS-4 collaborative group 1995). Importantly, any reduction of life-
threatening ventricular arrhythmias has not been confirmed, although VF tended to appear less 
frequently in the Mg2+ patient in the ISIS-4 study.  
3.3.5.3. Effect on postoperative arrhythmias 
Clinical studies on the effect of intravenously administered Mg2+ on supraventricular (mainly AF) 
arrhythmias after CABG have yielded inconsistent results. Although a fall in the postoperative 
serum Mg2+ concentration has been associated with the appearance of newly onset supraventricular 
arrhythmias, most of the studies where the Mg2+ dose has been just enough to correct the Mg2+
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decline or to raise it only moderately have not demonstrated any significant reduction in the 
incidence of these arrhythmias (Harris et al. 1988, Schwieger et al. 1989, England et al. 1992, 
Casthely et al. 1994, Møller Jensen et al. 1997). A 1.5 to 2-fold increase in serum levels of Mg2+ has 
been expected to achieve a reduction in this incidence (Fanning et al. 1991, Colquhun et al. 1993, 
Wistbacka et al. 1995), although a recent study showed benefit from a smaller increase (Speziale et 
al. 2000).
An increase in the serum concentration of Mg2+ ranging from near normomagnesemic to slightly 
hypermagnesemic levels has led to a detectable decrease in the incidence of ventricular arrhythmias 
(Harris et al. 1988, Swieger et al. 1989, England et al. 1992, Yurvati et al. 1992, Casthely et al. 
1994, Møller Jensen et al. 1997). Marked hypermagnesemia (1.5 times the upper reference limit) 
has produced mostly no effect (Fanning et al. 1991, Colquhun et al. 1993). In one study doubling of 
serum Mg2+ diminished the occurrence of ventricular arrhythmias (Wistbacka et al. 1995). It might 
be concluded that the available data speak for a true pharmacological effect of Mg2+ in reducing 
supraventricular (mainly AF) arrhythmias. Hypomagnesemia, or factors causing hypomagnesemia, 
appear to be a significant element in the genesis of postoperative ventricular arrhythmias. 
3.3.5.4. Effect on early afterdepolarizations-induced arrhythmias 
Treatment of TdP polymorphic VT aims at shortening the prolonged action potential and 
suppression of EADs. Traditionally, pacing at high ventricular rates, or temporary treatment with 
isoprenaline have been carried out (Jackman et al. 1988). Magnesium and, recently, potassium 
treatments have been shown to suppress the EADs and shorten the lengthened repolarization (Bailie 
et al. 1988, Kaseda et al. 1989, Choy et al. 1997). 
Experimental data. Experimentally induced EADs and VT can be reduced by Mg2+
administration. For example, the amplitude of cesium-induced EADs decreased significantly during 
infusion of MgSO4 (Bailie et al. 1988). The incidence and severity of ventricular arrhythmias were 
also diminished. In a canine model of chronic AV block and d-sotalol treatment, MgSO4 given as a 
fast bolus made EADs disappear and prevented induction of TdP (Vos et al. 1995, Verduyn et al. 
1997).
In addition to the suppression of EADs, Mg2+ administration shortenes the prolonged QT interval 
and MAP duration (Bailie et al. 1988, Verduyn et al. 1997). In the study of Verduyn and coworkers 
(1997), the shortening effect was significant on the left ventricular MAP duration but not on the 
right. Accordingly, Mg2+ resulted in the decrease of the interventricular, but not of the 
intraventricular dispersion of repolarization (Verduyn et al. 1997). The shortening effect of Mg2+ on 
quinidine-induced transmembrane action potential prolongation is only modest (Davidenko et al. 
1989). Magnesium shortens the QT duration in the drug-induced long QT syndrome with negative 
T waves, but not if the repolarization changes are caused by coronary artery disease (Gurfinkel et al. 
1993).
In conclusion, experimental findings suggest that Mg2+ prevents and terminates TdP 
polymorphic VT by suppression of EADs and shortening of the duration of the action potential. The 
mechanisms of these actions are not clearly understood. An increase in the intracellular 
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concentrations of K+ through activation of the Na+-K+ pump and blockade of the slow inward 
current may be involved. In isolated Purkinje fiber preparations exposed to quinidine, an elevation 
of the extracellular Mg2+ concentration eradicates phase 2 but not phase 3 EADs (Davidenko et al. 
1989). This finding led the authors suggest that Mg2+ may act either by inhibiting the slow inward 
current, or by a membrane stabilizing effect that shifts the EAD threshold potential in a positive 
direction (Davidenko et al. 1989). 
Clinical studies. The capability of Mg2+ to suppress TdP has been demonstrated also in patients. 
In twelve consecutive patients with the acquired long QT syndrome and TdP, one or two 
intravenous boluses of MgSO4 (2 g in 1 to 2 min) completely abolished the arrhythmia within 1-5 
min, although the QT interval was not shortened. In nine of the patients, a continuous infusion of 3 
to 20 mg/min for 7 to 48 h was used. The patients were not hypomagnesemic but most had 
hypokalemia (Tzivoni et al. 1988). Mg2+ was ineffective in suppressing polymorphic VT in patients 
with a normal QT duration (Tzivoni et al. 1988).  
3.3.5.5. Effect on other arrhythmias  
Digitalis-toxic arrhythmias. One of the first documentations of the antiarrhythmic effect of Mg2+ 
dealt with the treatment of ventricular arrhythmias in patients with digitalis toxicity (Zwillinger 
1935). Magnesium suppresses VTs induced by delayed afterdepolarizations due to experimental 
ouabain toxicity in dogs by mechanisms that are incompletely understood. The effect is evident in 
the absence of Mg2+ deficiency, and it is weaker than the effect of moricizine, a blocker of the fast 
inward Na+ current, and of verapamil, a blocker of the slow Ca2+ channel (Vos et al. 1994). In the 
intact digitalized and denervated canine heart, Mg2+ elevates the thresholds for VPBs and VF 
(Ghani and Rabah 1977). 
Ventricular arrhythmias in heart failure. In normomagnesemic patients with chronic NYHA 
II - IV heart failure, a twofold increase in serum Mg2+ levels following Mg2+ infusion results in a 53 
% reduction in the total number of VPBs, a 76 % reduction in couplets, and a 69 % reduction in 
episodes of VT compared with placebo-treated patients. The effect is not related to the pretreatment 
serum Mg2+ concentration. In this study the patients were treated with standard medication 
excluding antiarrhythmics or -blockers (Sueta et al. 1994). In a more recent controlled study, a 
significant reduction in the incidence of VPBs, couplets and nonsustained VTs was also 
demonstrated (Ceremuynski et al. 2000). Uncontrolled studies with a small number of patients 
have yielded consistent responses to Mg2+ infusion (Frustaci et al. 1987, Perticone et al. 1990, 
Gottlieb et al. 1993). A relation to Mg2+ depletion has been observed in some of these studies and a 
dose dependent effect in most.  
Supraventricular reentrant tachycardias. In a series of 10 normomagnesemic patients with 
AV nodal or AV reentrant tachycardia, a rapid intravenous bolus of 2 g of MgSO4 terminated the 
tachycardia in 7 of the patients abruptly. A second bolus was needed in one patient (Wesley et al. 
1989). The response seemed to be identical in both forms of the tachycardia. In contrast, Sager and 
coworkers (1990), in a similar subset of patients with induced sustained arrhythmia, could 
demonstrate termination in only 2 of the 11 patients (most probably resulting from spontaneous 
nonsustained VT). Viskin and coworkers (1992) compared the efficacy of Mg2+ and adenosine 
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triphosphate in 15 patients with electrophysiologically induced orthodromic AV or AV nodal 
reentry tachycardia. Adenosine triphosphate terminated every SVT, whereas Mg2+ (2 g in 15 
seconds) did so in only 6 of their patients. 
In all of these studies, Mg2+ increased the tachycardia cycle length significantly. The slowing of 
the tachycardias was due to effects in the antegrade AV nodal pathway (Sager et al. 1990, Viskin et 
al. 1992). Magnesium has no effect on the distal AV conduction, and retrograde conduction through 
the AV node is not delayed (Wesley et al. 1989, Sager et al. 1990, Viskin et al. 1992). Retrograde 
block in the accessory pathway occurs variably but antegrade conduction over the bypass tract is 
not affected (Wesley et al. 1989, Sager et al. 1990, Viskin et al. 1992). These findings contrast with 
a preliminary report of a transient disappearance of the delta wave by Mg2+ (Sideris et al. 1996). 
Thus, interruption of SVT has been obtained in 20-80 % of the cases, either by blocking the 
antegrade AV nodal conduction or the retrograde conduction over the accessory pathway. Rapid 
administration but not the final serum Mg2+ levels differentiated the responders. 
It is not known how Mg2+ exerts these effects on AV nodal or accessory pathway conduction at 
the cellular level. The proposed mechanisms involve slow Ca2+ channel blockade (Iseri and French 
1984) and a sympatholytic or parasympathomimetic action (Stanbury 1948, von Euler and Lishajko 
1973).
Other atrial arrhythmias. The first documented cases of successful treatment of atrial 
tachycardias with Mg2+ originate in the report of Boyd and Scherf (1943), who reached a 55 % 
conversion rate in a group of patients with heterogeneous atrial arrhythmias not associated with 
digoxin therapy. More recently, Moran and coworkers (1995) compared Mg2+ with amiodarone in 
the conversion of atrial tachycardias (mostly AF) in critically ill patients being treated in the 
intensive care unit. Magnesium was superior to amiodarone in restoring normal sinus rhythm within 
24 h (78 % vs 50 %, respectively). In multifocal atrial tachycardia, an injection of MgSO4 restored 
normal sinus rhythm temporarily in 78 % of patients compared to 20 % in controls. It also 
decreased significantly the ventricular rate during the arrhythmia before conversion (McCord et al. 
1998). This result complies with a previous uncontrolled experience (Iseri et al. 1985). 
Other ventricular tachycardias. Some case reports have described a beneficial effect of Mg2+
in the treatment of patients with VT not associated with digitalis intoxication, overt 
hypomagnesemia, AMI, heart failure, or the acquired long QT syndrome. Usually, Mg2+ was 
applied after conventional antiarrhythmic therapy had failed (Iseri et al. 1983, Allen et al. 1989). 
Hilton and coworkers (1992) have shown that none of the 10 normomagnesemic patients presenting 
with life-threatening sustained ventricular arrhythmias became non-inducible in programmed 
electrical stimulation after Mg2+ administration. Furthermore, Mg2+ did not affect the mode of 
induction and termination, the type and morphology, and cycle length and ventricular refractoriness. 
In concordance, in a study of postinfarction patients with electrophysiologically induced sustained 
monomorphic VT, the VT was terminated in only 1/16 patients (Farouque et al. 2000). In patients 
with in-hospital cardiac arrest, mostly secondary to VT and VF, magnesium given during 
resuscitation failed to improve the return of spontaneous circulation or the overall prognosis (Thel 
et al. 1997). 
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3.3.5.6. Summary of the effects on cardiac arrhythmias 
In conclusion, Mg2+ depletion or hypermagnesemia exert only minor or no effect on normal atrial or 
ventricular muscle or Purkinje fiber cells. On the other hand, magnesium can diminish or eliminate 
the unfavorable electrophysiological responses elicited by hypocalcemia, hypokalemia, 
hyperkalemia and pathophysiology behind the creation of EADs during ventricular repolarization. It 
has a significant negative dromotropic effect on the AV node. Prevailing data show that Mg2+
therapy is of potential efficacy in the treatment of triggered and of those reentrant arrhythmias 
where the critical structures are Ca2+-dependent. Arrhythmias involving scar-based reentry are not 
suppressible, probably because refractoriness and conduction, the determinants of initiation and 
perpetuation of the reentrant circuit, are only modestly or not at all affected by Mg2+ administration.
4. AIMS OF THE STUDY 
The present study was planned to test the following hypotheses: 
I. Postoperative hypomagnesemia in patients undergoing CABG is associated with the occurrence 
of AF, and the development of AF can be prevented by intravenous administration of Mg2+ in
pharmacological doses. 
II. Postoperative decline in the serum Mg2+ concentration in patient undergoing CABG is associated 
with the occurrence of ventricular arrhythmias, and the incidence of these arrhythmias can be 
reduced by pharmacological doses of Mg2+.
III. A rapid intravenous infusion of Mg2+ to patients with no or only mild heart disease changes 
ventricular refractoriness and duration of the action potential of the ventricular muscle measured by 
MAP recording. 
IV. Intravenous administration of Mg2+ in the early phase of infarction to patients with AMI can 
suppress ischemic arrhythmias of recent onset. The response is mediated by influence on some of 
the pathophysiologic determinants of the generation of ischemic arrhythmias, i.e., autonomic 
regulation of the heart (HRV, BRS), inhomogeneity in repolarization (electrocardiographic QT 
dispersion), ischemia, and the extent of myocardial injury. 
V. An intravenous infusion of Mg2+ induces intracellular Mg2+ and K+ changes in patients 
hospitalized for cardiac arrhythmias and this effect can be monitored comparably in mononuclear 
cells and skeletal muscle tissue.  
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5. METHODS 
5.1. Subjects 
One hundred and forty consecutive patients who underwent CABG for the first time were 
randomized to receive either Mg2+ (n = 69) or placebo (n = 71). Excluded were patients having 
concurrent valvular replacement or arrhythmia surgery procedures as well as patients with chronic 
AF or on antiarrhythmic medication. Treatment with -blockers, digitalis and calcium antagonists 
was allowed. The study groups were comparable with regard to most preoperative characteristics. 
However, patients in the magnesium group were slightly older, prior AF was more common among 
them, and, probably due to this, their digitalis use was more frequent. One patient who died on the 
first postoperative day because of graft occlusion and consequent perioperative myocardial 
infarction was excluded from the postoperative analysis. Therefore, in the final postoperative 
analyses the number of patients in the control group is 70. Another patient, yet included for 
analysis, had postoperative cerebral thrombosis and died of massive pulmonary embolism four 
weeks after the operation. The preoperative characteristics of the patients are summarized in Table 
1 (Studies I and II). 
The two study groups did not differ with respect to total cardiopulmonary bypass time, aortic 
cross clamp time, amount of cardioplegic solution used, myocardial temperature, energy needed for 
defibrillation to sinus rhythm following perfusion or need for prolonged temporary pacing. The 
proportion of patients with three vessels revascularized was 72 % in the magnesium group and 76 % 
in the control group (NS), and patients experiencing perioperative myocardial infarction 13 % and 
24 %, respectively (NS). The number of anastomoses per patient was 4 ± 1 in both groups. In 
addition to vein grafts, a total of 87 mammary artery grafts (1.3 per patient) in the active treatment 
group and 98 (1.4 per patient) in the control group were performed. 
Study III comprised 12 patients admitted for electrophysiologic testing for clinical indications. 
There were 6 males and 6 females aged 59 ± 12 years (range 18 - 66 years). Seven patients with the 
Wolff-Parkinson-White syndrome had a control test after operative disconnection of the accessory 
pathway. Two patients had sustained monomorphic VT without apparent heart disease. Two 
patients without heart disease were tested for syncope of unknown etiology. One patient had 
dilative cardiomyopathy and a history of VF. Two of the patients had essential hypertension that 
was controlled with metoprolol and a combination of a thiazide and a K+ sparing diuretic that were 
not discontinued. Patients with digitalis were excluded. All antiarrhythmic drugs including β-
blockers were withheld before the study for at least five half-lives. None of the patients had 
myocardial hypertrophy, right ventricular pathology or significant valvular disease by Doppler 
echocardiography. The mean left ventricular EF was 59 ± 12 % (range 34 - 74 %) and the mean left 
ventricular end diastolic diameter 52 ± 6 mm (range 45 - 66 mm). None of the patients were 
hypomagnesemic and their serum levels of Na+, K+, Ca2+ and creatinine were within the reference 
range. Before entering the study, the antecedent clinical investigations had to be completed with no 
need for electrical cardioversion, isoprenaline or other vasoactive agents, or any antiarrhythmic 
medication. No patient had sustained tachycardia induced (Study III). 
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Table 1. Preoperative characteristics of the patients with CABG.
Magnesium 
(n = 69) 
Control 
(n = 71) 
Age (years) 57 ± 8 54 ± 8* 
Male gender (%) 84 82 
NYHA functional class 2.8 ± 0.7 2.9 ± 0.8 
LVEDP (mmHg) 10 ± 5 12 ± 6 
LVEF (%) 61 ± 14 59 ± 14 
LVEDD (mm) 54 ± 7 55 ± 7 
LA (mm) 39 ± 5 41 ± 5+
Heart rate (beats/min) 56 ± 10 56 ± 8 
Serum K+ (mmol/l) 4.14 ± 0.27 4.11 ± 0.32 
Serum Mg2+ (mmol/l) 0.83 ± 0.07 0.84 ± 0.08 
Serum creatinine (mol/l) 94 ± 14 94 ± 18 
Patients with   
      three-vessel disease (%) 78 79 
      left main disease (%) 9 10 
      prior AF (%) 9 1+
      prior hypertension (%) 38 39 
      prior AMI (%) 58 58 
      prior Q wave (%) 38 42 
Treatment with         
-blocker (%) 86 85 
      Diuretic (%) 12 10 
      Digitalis (%) 12 3* 
Ca2+ -antagonist 70 69 
Data are mean ± standard deviation unless otherwise specified.  
NYHA = New York Heart Association; LV = left ventricle; EDP = end diastolic 
pressure; EF = ejection fraction in biplane cineangiography; EDD = end 
diastolic diameter in echocardiography; LA left atrial systolic diameter in 
echocardiography; AF = atrial fibrillation; AMI = acute myocardial infarction. 
p < 0.05 between the groups; +  p < 0.1 between the groups. 
In Study IV, 59 consecutive subjects with AMI and < 12 h from onset of chest pain were 
randomized. They were identified after screening all patients aged < 75 years admitted to the 
cardiac care units of the Meilahti Hospital of the Helsinki University Central Hospital, Helsinki, 
Finland and Jorvi District Hospital, Espoo, Finland. Excluded were patients with the sick sinus 
syndrome, AF, second or third degree AV conduction block, insulin dependent diabetes mellitus, 
uncontrolled arterial hypertension, or serum creatinine concentration > 250 mol/l. Also patients 
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with significant stenotic valvular disease, permanently paced rhythm or need for immediate 
ventilator treatment were ineligible. The demographic data are summarized in Table 2 (Study IV). 
Table 2. Demographic data of the patients with AMI.
Magnesium 
(n = 69) 
Control 
(n = 26) 
Age (years) 60 (30 – 73) 59 (36 – 74) 
Male gender 26 (84) 22 (85) 
Prior AMI 3 (10) 3 (12) 
Prior –blocker 6 (20) 6 (23) 
Prior aspirin 1 (3) 1 (4) 
Diabetes 2 (6) 2 (8) 
Hypertension 7 (23) 6 (23) 
The values are median (range), or numbers (percentage).  
AMI = acute myocardial infarction. 
The groups were statistically equal. 
The characteristics of the patients with AMI are summarized in Table 3. Non Q wave AMI was 
equally distributed but anterior Q wave AMI was more prevalent in the patients on active treatment 
and inferior AMI in the controls. The time from onset of fibrinolytic treatment to onset of the study 
treatment was 5.3 h (1 - 10.5 h) in the magnesium group and 5.0 h (2 - 10 h) in the control group 
(NS). Three patients, all in the control group, experienced conduction disturbances: one patient had 
persistent grade I AV block, one persistent left anterior hemiblock and one temporary grade II AV 
block of the Wenckebach type. During the study period, diuretics and angiotensin converting 
enzyme inhibitors were given in both groups to a similar extent. 
In study V, 11 patients, 10 male and 1 female aged 51 ± 9 years (range 39 - 63 years), were 
selected for the study on the basis of underlying cardiac disease and hospitalization for arrhythmias 
necessitating specific treatment. Five underwent electrophysiologic testing. The mean left 
ventricular EF was 31 ± 17 % (range 10 - 60%) determined by biplane cineangiography, M-mode 
echocardiography or radionuclide ventriculography. All patients had antiarrhythmic medication. Six 
were treated with an angiotensin converting enzyme inhibitor and six patients used diuretics. Two 
patients had diabetes mellitus. Patients with unstable angina pectoris, recovery phase of an AMI, 
significant conduction disturbances, decompensated heart failure, poorly controlled diabetes 
mellitus, a serum creatinine above 150 mol/l or a blood pressure below 90/60 mmHg were 
ineligible for the study. The clinical characteristics are shown in Table 4 (Study V). 
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Table 3. Clinical profile and treatment of the acute myocardial infarction during the first 24 h.
Magnesium 
(n = 31) 
Control 
(n = 26) 
Anterior Q wave AMI 16 (52) 6 (23)* 
Inferior Q wave AMI 9 (29) 14 (54)* 
Fibrinolytic treatment 28 (90) 23 (88) 
Time to fibrinolytic treatment (h) 2.0 (1 – 9) 3.5 (0.5 – 9) 
Time to study medication (h) 8 (5.5 – 12) 9 (5 – 12) 
Intravenous -blocker use 16 (52) 12 (46) 
Aspirin use 25 (81) 22 (85) 
Serum Mg2+, baseline (mmol/l) 0.78 (0.61 – 0.93) 0.78 (0.66 – 0.99) 
Serum Mg2+, at 24 h (mmol/l) 1.30 (1.11 – 1.74) 0.74 (0.61 – 0.92)*** 
Serum K+, baseline (mmol/l) 3.90 (3.50 – 4.50) 4.00 (2.80 – 5.10) 
Serum K+, at 24 h (mmol/l) 4.10 (3.50 – 4.70) 4.00 (3.50 – 5.00) 
Serum peak CK-MB (g/l) 113 (7 – 1106) ) 181 (12 – 639) 
Values are median (range) or numbers (percentage). 
AMI = acute myocardial infarction; CK-MB = creatine kinase MB. 
*  p <0.05; ***  p <0.001 between the groups. 
Table 4. Patient characteristics in the study of intracellular measurements. 
Patient Heart disease Type of 
arrhythmia 
Left ventricular 
EF (%) 
Diuretic therapy 
MH AMI VT 21 Yes 
RH DCMP VT, VF 36 No 
KJ CAD NSVT 60 No 
VK AMI VT, VF 43 No 
PN AMI NSVT 17 Yes 
EN AMI NSVT 13 Yes 
AS AMI AF - Yes 
KS AMI AF, NSVT 49 Yes 
SS AMI VT, VF 35 No 
PS AMI VT 24 Yes 
IV AMI VT 10 No 
AMI = remote acute myocardial infarction; CAD = coronary artery disease without myocardial 
infarction; DCMP = nonischemic dilative cardiomyopathy; NSVT = nonsustained ventricular 
tachycardia; other abbreviations as indicated in ABBREVIATIONS. 
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5.2. Coronary artery bypass grafting technique 
The operations were performed by the standard technique of the institution and consisted of mild 
hypothermia, topical cooling and cardiac arrest. Cardiac protection was induced by cold crystalloid 
antegrade cardioplegic solution containing 120 mmol/l Na+, 8 mmol/l K+, 16 mmol/l Mg2+, 1.2 
mmol/l Ca2+, 160 mmol/l chloride and 10 mmol/l bicarbonate (Studies I and II).  
5.3. Definitions of arrhythmias 
Atrial fibrillation.  AF was defined as irregular QRS complex intervals and no detectable regular 
atrial activity. It was defined as clinical AF if it lasted for one hour or less if treatment was 
necessitated because of intolerable symptoms or hemodynamic deterioration. An episode of AF on 
Holter recording was characterized as the rhythm defined above continuing for 15 seconds and at 
least one minute apart (Study I).  
Other supraventricular arrhythmias.  The total number of supraventricular premature beats 
per hour was calculated from Holter recordings. SVT was defined as three or more consecutive 
premature beats at a rate of > 120/min (Studies I and IV). 
Ventricular arrhythmias.  The total number of PVBs per hour was measured. Three or more 
consecutive PVBs at a rate of > 120 beats/min were classified as VT (Studies II and IV). VT < 120 
beats/min was a slow VT  (Study IV).  
In Study II, a modified Lown classification of the PVBs was used as follows: 0 = no PVBs; 1 = < 
30 PVBs/h; 2 = > 30 monomorphic PVBs/h; 3 = polymorphic (≥ 3 morphologies) PVBs when the 
total frequency was > 20 PVBs/h; 4 = couplets or VT; 5 = R-on-T phenomenon (Lown and Wolf 
1971).
Classes 0 and 1 of the modified Lown classification were graded as simple and classes 2 to 5 as 
complex ventricular arrhythmias. 
To test the overall ventricular arrhythmicity during the postoperative decline in serum Mg2+
concentration (days 2 and 3), the patient was defined as having a high risk ventricular arrhythmia if 
he or she experienced one of the following on Holter recording either on the second or third day: 1 
= repetitive polymorphic (≥ 3 morphologies) PVBs; 2 = repetitive couplets or a period of VT; 3 = 
repetitive R-on-T phenomenon. Of the 120 patients with analyzable Holter data, 20 fulfilled the 
criteria. 
5.4. Definition of acute myocardial infarction  
The criteria used for AMI consisted of chest pain of > 20 min duration, combined with ST segment 
elevation of ≥ 0.1 mV in ≥ 1 of the limb leads or ≥ 0.2 mV in ≥ 2 of the chest leads, or a rise in 
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serum creatine kinase MB isoenzyme (CK-MB) mass unit to > 7 g/l. CK-MB was measured on 
admission and three times at 12 h intervals successively. The localization was considered as anterior 
if the changes occurred in chest leads V2-V6, and inferior in leads II, III, and AVF. The AMI was 
defined as a Q wave AMI, if a new Q wave of ≥ 40 ms emerged (Study IV).  
Perioperative AMI was defined as a new pathological Q-wave appearing on 12-lead ECG, or 
creatine kinase MB isoenzyme at a concentration of >100 IU measured on the first postoperative 
day (Studies I and II).  
5.5. Arrhythmia detection 
Cardiac rhythm was monitored continuously with bedside monitors for the first two postoperative 
days in the intensive care unit. Thereafter for up to ten days, every symptomatic palpitation was 
recorded on a 12-lead electrocardiogram and analyzed by the same reviewer (Studies I and II). 
Two-channel Holter recordings were performed as follows: In Studies I and II, a 48 h recording 
(Instruments for Cardiac Research 7200) was started on the second postoperative day. In Study IV, 
two 24 h recordings (Marquette 8500, Marquette Electronics Inc., Milwaukee, Wi, U.S.A.) were 
performed. The first was started prior to the administration of the study infusion. The second was 
accomplished prior to discharge from hospital on the 7th to 14th day, after the patient's condition 
had stabilized. The tapes were analyzed blindly by the same observer with a Marquette 8000 Holter 
Analysis System utilizing the 5.8 software. The automatic QRS classification was edited when 
necessary. 
5.6. Electrocardiographic measurements 
Serial standard 12-lead electrocardiograms taken at a paper speed of 50 mm/s were recorded 
preoperatively and daily during the five postoperative days (Studies I and II). In Study IV they were 
recorded immediately on arrival to the hospital (baseline), 24 h after the start of the study treatment 
and prior to discharge. Of these, sinus cycle length, PQ interval and QRS durations were analyzed 
by standard criteria from lead II or V2. The QT interval was measured from the beginning of the Q 
or R wave to the point where a tangent drawn along the maximal slope of the decending limb of the 
T wave (or ascending when T wave was inverted) crossed the isoelectric TP baseline. If a biphasic 
T wave was present, the latter part was used for drawing. A separate U wave was disregarded. In 
cases where the T wave was isoelectric or the termination of the T wave could not be reliably 
calculated the lead was excluded from the analysis (Lepeschkin and Surawicz 1952). QT interval 
measurements were calculated from three consecutive sinus beats and averaged (Study IV). 
5.7. Measurement of ischemia and size of myocardial infarction 
Continuous on-line VCG using the MIDA 1000 computer program (Ortivus Medical AB, Täby, 
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Sweden) was started 15 min before the study infusion (Study IV). In MIDA, the orthogonal Frank 
lead system is used to compute VCG signals, which are averaged over 2-min periods. The first 2-
min average period formed the reference and all changes were compared with it. The VCG 
parameters used were QRS vector difference (QRS-VD), ST vector magnitude (ST-VM) and ST 
change vector magnitude (STC-VM) (Lundin et al. 1992). An ischemic episode was defined as a 
reversible increase in QRS-VD by >15 Vs from the current base level lasting > 2 min, or a 
reversible increase in ST-VM or STC-VM by > 0.1 mV (Lundin et al. 1992). 
On Holter recording, an ischemic event was defined as ST depression of ≥ 1 mm measured 80 
ms after the J point, lasting for ≥ 1 min and at least 1 min apart (Studies I, II, IV).  
A symptom limited bicycle exercise test using 3-min steps and 25 W increments in work load 
was performed prior to discharge. ST depression of ≥ 1 mm measured 80 ms after the J point was 
defined as ischemia (Study IV). 
The height of the rise in the serum creatine kinase MB isoenzyme (CK-MB) mass unit was used 
to quantify the myocardial necrosis (Study IV).  
5.8. Measurement of inhomogeneity of repolarization 
QT dispersion was defined as the difference between the maximal and the minimal QT duration 
appearing in any of the 12 leads and corrected for heart rate (QTcD) according to the formula by 
Bazett, QTc=QT/RR1/2 (Bazett 1920). At least 9 analyzable leads in each recording were needed. 
All the measurements were done blindly by the same observer (Study IV). 
5.9. Measurement of autonomic regulation of the heart 
Heart rate variability was assessed by time domain and frequency domain methods from the 24 h 
Holter recordings. To calculate HRV, the software used only normal sinus beat intervals. Ectopic or 
artifact periods were excluded and replaced by holding the previous coupling interval level through 
to the next valid coupling interval. Fast Fourier Transformation was used to separate the R-R 
fluctuations to frequencies. The spectral bands used were 0.15-0.40 Hz (high frequency; HF) and 
0.04-0.15 Hz (low frequency; LF). The spectral measures were computed as amplitudes, which are 
square roots of areas under power spectrum, and were presented in ms. The areas represent signal 
variance within frequency bands while the square root represents the standard deviation. The HF 
and LF components were determined from the entire 24 h recording. The LF/HF amplitude ratio 
was calculated and used as an indicator of sympatho-vagal balance (Task Force of The European 
Society of Cardiology and The North American Society of Pacing and Electrophysiology 1996). 
The standard deviation of the averaged normal-to-normal R-R intervals for all 5 min periods of the 
24 h recording (SDANN) was used as the time domain method. During the first recording the 
patients were resting but during the second they were allowed normal activity (Study IV).  
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Baroreflex sensitivity was detected prior to discharge (Study IV). BRS was assessed by plotting 
each beat-to-beat R-R interval against the preceding systolic arterial pressure obtained by invasive 
recording. To provoke this, an intravenous 0.1 mg phenylephrine bolus was used. It was increased 
in steps of 0.05 mg until an anticipated 15 - 40 mmHg rise in systolic pressure was observed (Smyth 
et al. 1969). The mean of three slopes of linear regression lines with correlation coefficient ≥ 0.8 
was defined as BRS index (ms/mmHg). Data recording and analysis was performed with a specific 
software package (Cafts, Medikro Oy, Finland).  
5.10. Electrophysiological measurements 
In Study III, all patients underwent an initial standard electrophysiologic study. Three conventional 
6F quadripolar electrode catheters were advanced through the right femoral vein and positioned 
inside the heart as clinically indicated. Systemic blood pressure was monitored with a 5F cannula 
introduced into the right femoral artery or with a sphygmomanometer. Bipolar cardiac stimulation 
(cathode distal) was performed with a programmable stimulator (Bloom Associates Ltd., Reading, 
PA, USA) using stimuli of 2 ms duration and twice the late diastolic threshold. A bipolar 
silver/silver chloride contact electrode catheter (006248, C.R. BARD Inc., Billerica, MA, USA) was 
used for the MAP recordings.  
5.10.1. Monophasic action potential recording  
MAPs were recorded by positioning the catheter with gentle pressure in the low apical septal 
endocardium of the right ventricle. Signals were amplified and filtered at a frequency of 0.05 - 20 
Hz. The tracings were accepted for analysis when configurations showed a rapid early systolic 
upstroke followed by a plateau and a downsloping repolarization phase without superimposed 
intracardiac QRS deflections. Diastolic potentials shifting prominently upwards or repolarization 
phases ending with a deep negative depression were not accepted. The waveforms had to be stable 
in amplitude and duration both during sinus rhythm and atrial pacing. Only MAPs of more than 10 
mV in amplitude were accepted. MAPs were recorded from the same site throughout the study 
during sinus rhythm and atrial pacing at a cycle length of 600 ms.  
MAP tracings were registered together with ECG leads I, II and V6, arterial pressure and right 
ventricular apical intracardiac electrogram on a Siemens-Elema Mingograph recorder (Siemens-
Elema, Solna, Sweden) at a paper speed of 100 mm/s. A minimum of 30 s at a stable rate was 
required before the registration. The duration of the MAP at 50 % and 90 % of the repolarization 
during sinus rhythm (MAPD50 and MAPD90) and atrial pacing (MAPD50600 and MAPD90600) were
measured (Figure 1). In cases of a rapid biphasic deflection on the initial phase of the MAP the fast 
negative slope of this intrinsic deflection was used as the beginning of the MAP (Franz 1991) 
(Study III).  
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of this suspension was used for the cell count. The rest of the suspension was centrifuged at 1000 g 
for 15 min and the supernatant removed. The cells were lyzed by mixing with 200 l of destilled 
water and frozen and thawed three times by incubating in an ethanol-ice mixture. Two 5 l samples 
were frozen for protein analysis that was later performed by the method of Lowry et al. (1951). The 
rest of the cell lysate was centrifuged in an Eppendorf tube at 8000 g for 5 min. The Mg2+
concentration was then determinated with atomic absorption spectrophotometry and K+ with flame 
photometry. The results are expressed both as nanomole per milligram of protein (nmol/mg prot) 
and femtomole per cell (fmol/cell). 
The skeletal muscle samples were taken by a percutaneous needle biopsy from the lateral portion 
of both vastus lateralis muscles approximately 15 cm above the knee by the method originally 
published by Bergström (1962). After removal of blood, fat and visible connective tissue the sample 
was frozen in dry ice and stored at -75oC until analyzed. The biopsy samples were weighed and 
added to 0.3 ml of frozen 0.6 mol/l perchloric acid (PCA) containing 5.86 g/l lanthanum oxide and 
homogenized mechanically. After melting the sample was centrifuged at 500 g for 15 min and the 
supernatant was collected. The pellet was mixed with 0.3 ml of PCA, homogenized and centrifuged 
and the supernatant collected. The procedure was repeated once. The pellet was suspended in 2 ml 
of 1 mol/l NaOH and after a 30 min period incubated for 10 min in warm water and ultrasonicated. 
The protein content was then measured (Lowry et al. 1951). A volume of 0.7 ml of the pooled 
supernatants was diluted with 2.5 ml of PCA-lanthanum oxide and analyzed for Mg2+ concentration 
by atomic absorption spectrophotometry. The undiluted supernatant was used for K+ determination 
by flame photometry. The results are expressed as nanomoles per mg of protein (nmol/mg prot) and 
as millimoles per kilogram of wet weight (mmol/kg ww). 
5.12. Other assessments 
5.12.1. Serum magnesium measurement 
Serum Mg2+ concentrations were determined by atomic absorption spectrophotometry. Under the 
postoperative period, serum Mg2+ was measured on the first, third and fifth days (Studies I and II). 
In the other studies it was measured before the study treatment started and at the end of it. In Study 
III, an intermediate analysis was performed after the loading infusion. The reference range for the 
serum Mg2+ concentration was 0.70 - 1.00 mmol/l. 
5.12.2. Other laboratory analyses 
Serum K+ concentrations were measured by using an ion-selective electrode in connection with the 
Mg2+ determinations in every study. In addition, serum Na+, Ca2+, creatinine, C-reactive protein and 
hematology were assessed in the postoperative patients on the first, third and fifth days (Studies I 
and II). In other studies, they were assessed prestudy or when clinically indicated. 
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5.12.3. Other measurements 
Left ventricular dimensions and systolic function were assessed from preoperative biplane 
cineangiographies (Studies I and II), or by two dimensional and M-mode echocardiography 
recordings performed by standard methods (all studies). The latter registrations were carried out as 
preinterventional procedures in Studies I - III and V, serially to detect pericardial effusion as well in 
Studies I and II (third and tenth days), and as a predischarge investigation in Study IV. 
The presence of a late potential was determined using a commercially available signal averaged 
electrocardiogram recording method. Total filtered QRS duration, root-mean-square (RMS) voltage 
in the terminal 40 ms and duration of HFLA signals below 40 V were calculated (Marquette 
Electronics MAC-12/15, Millwaukee, WI, U.S.A.). The criteria for a positive late potential included 
QRS duration >110 ms, RMS voltage <25 mV and HFLA duration >35 ms. The mean ± SD noise 
voltage was 0.6 ± 0.3 V (Study IV). 
Data on medical history, patient characteristics and coronary angiograms were collected from the 
patient files. 
5.13. Magnesium administration 
In the patients who underwent surgery, the study infusion was started within 2 h after chest closure. 
A total of 70 mmol of MgSO4 was infused: during the first 24 h 40 mmol in 1 l of 5 % glucose-in-
water solution, and 30 mmol in 500 ml during the next 24 h. The vehicle served as placebo (Studies 
I and II). 
In examining the rapid electrophysiologic effects of Mg2+, a loading infusion of 12 mmol of 
MgSO4 in 100 ml of 5 % glucose-in-water solution was given in 10 min, followed by a maintenance 
infusion of 8 mmol/h (Study III). 
Patients with AMI had the study infusion started after beginning of fibrinolytic therapy. An 8 
mmol bolus was given in 10 min followed immediately by 62 mmol in 500 ml of physiologic NaCl 
infused over 24 h. The corresponding volumes of NaCl solution served as placebo in controls 
(Study IV). 
In the study of the intracellular kinetics of Mg2+, 30 mmol of MgSO4 in 500 ml of 5 % glucose-
in-water was infused within 12 h at a constant rate (Study V).  
The MgSO4 administration protocol used in the studies aimed at testing the antiarrhythmic 
potential of Mg2+ by increasing the serum Mg2+ concentration about twofold. The target level 
corresponds with serum Mg2+ levels in reports where Mg 2+ has shown efficacy. 
56
5.14. Study designs 
The studies comparing the effects of Mg2+ and placebo were carried out in a randomized, double-
blind manner (Studies I, II, and IV). The studies testing the physiological and pathophysiological 
responses to Mg2+ administration, where the patients served as their own controls, were run openly 
(Studies III and V). 
5.15. Statistical methods 
Continuous data of normally distributed parameters are expressed as mean ± standard deviation. 
Median and range were used to describe non-normally distributed variables. To enable parametric 
testing in such non-normal variables, natural logarithmic transformation was incidentally 
performed. Student’s t test and Wilcoxon’s signed-rank test were used for paired comparisons, 
respectively. Serial within group effects were compared using analysis of variance with repeated 
measures or Friedman’s statistics, including Bonferroni’s adjustment. Group differences were 
compared with Mann-Whitney rank-sum test, or analysis of variance, applying the Tukey method 
for multiple comparisons between pairs of means (Glantz 1987). 
Categoric variables were compared with Fisher’s two-tailed exact test or chi-square test, with a 
test for linear trend when appropriate (Glantz 1987). 
Correlations between various variables were analyzed with the Pearson product-moment 
correlation coefficient, or with the Spearman rank correlation test (Glantz 1987). 
Multivariate analysis was done to search for mechanisms behind the occurrence of postoperative 
AF or high risk ventricular arrhythmias by stepwise logistic regression analysis using a p-value of 
0.10 as the enter limit for the variables. For this procedure, missing data (mean 1.4 % of variables 
per case) were replaced by computing the estimates using the twostep method in AM program of 
BMDP software (Frane 1985). 
To test the intraobserver reproducibility of the monophasic action potential duration 
measurements, the recordings of four patients were analyzed twice. Linear regression between the 
two measurements and calculation of the repeatability coefficient (root-mean square of differences 
between the two sets of measurements) were determined as the estimates. Twice the latter 
coefficient (in ms) represents the 95 % confidence interval for absolute values of differences in 
paired determinations (Bland and Altman 1986). 
All the analyses were performed on an intention-to-treat basis. The computations were 
performed by using the SYSTAT (SYSTAT Inc., Evanston, IL, USA) and the BMDP (BMDP, 
Berkeley, CA, USA) statistical software. The null hypotheses were rejected at a two tailed p-value 
level of <0.05. 
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6.2. Effect of magnesium on postoperative arrhythmias  
6.2.1. Atrial fibrillation and other supraventricular arrhythmias 
The incidence of clinical AF was 29 % (n=20) in the magnesium group and 26 % (n=18) in the 
control group (NS). The mean time to the first AF was 3.5 ± 1.9 and 3.8 ± 2.7 days, respectively 
(NS). Atrial fibrillation relapsed in nine patients (45 %) in the group receiving magnesium and in 11 
patients (61 %) in the control group (NS). AF did not become persistent in any patient. SVT 
necessitating treatment occurred in one control patient. 
Holter recordings did not reveal any new AF patient that had not been identified by clinical 
symptoms. The incidence of AF was 15 % and 13 % in the magnesium and control group, 
respectively (NS). The total number of AF episodes, their duration or ventricular rate did not differ 
between the groups. The incidence of SVT was 39 % and 30 %, respectively (NS). 
Factors associated with the occurrence of postoperative AF. In the patients with AF, serum 
Mg2+ concentration tended to be higher on the first postoperative day (0.99 ± 0.25 versus 0.90 ± 
0.19 mmol/l; p = 0.063), and was significantly higher on the third day (0.89 ± 0.21 versus 0.80 ± 
0.11 mmol/l; p <0.01) in comparison with the non-AF patients. The incidence of AF in the highest 
quartile of serum Mg2+ on the first day was 43 % (12/28) compared with 23 % (26/111) among the 
rest of the patients (p = 0.056). 
In the patients with AF, the sinus rate on the first day (measured from ECG) tended to be slower 
(82 ± 14 versus 86 ± 11 beats/min; p = 0.076), and the mean sinus rate (Holter recording) was 
significantly slower on the second day (78 ± 10 versus 86 ± 12 beats/min; p <0.01). Among the 
patients with AF, there was an inverse correlation between the magnitude of the change in the sinus 
rate from before the operation to the second postoperative day and serum Mg2+ concentration on the 
first day (r = –0.455, p = 0.044) and on the third day (r = –0.407, p = 0.054). 
When the sinus rates and serum Mg2+ concentrations of those 23 patients whose AF occurred 
during the first three days (23/38 = 61 % of all the AF patients) were compared to those who did not 
experience AF, serum Mg2+ levels were higher and sinus rates slower on each of the first three 
postoperative days in the AF patients (Table 5).  
Factors in the magnesium group. In the AF patients in the magnesium group, the serum Mg2+
concentration on the first postoperative day was higher than in the patients without AF (1.20 ± 0.17 
versus 1.04 ± 0.15 mmol/l; p = 0.001). When the serum Mg2+ concentration on the first day was 
divided into its four quartiles (<1.03, 1.03 - 1.09, 1.09 - 1.17, >1.17 mmol/l), the incidence of AF 
grew from the lowest and reached a 47 % incidence in the highest quartile (p = 0.016 by the test for 
linear trend) (Figure 3). 
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When only those AF patients whose arrhythmia occurred within the first three postoperative days 
were considered, the sinus rates were decreased on the second and third days in the magnesium but 
not in the control group. The sinus rates of the AF patients in the magnesium group tended to be 
slower than of the AF patients in the control group (Table 6).  
Table 6. Sinus rates (beats/min) in the treatment groups in patients with atrial fibrillation (n = 23) 
on the  first 3 days compared with non-atrial fibrillation patients. 
   Postoperative day   
  0 1 2  3  
        
Magnesium group AF 57 ±10 79 ± 12 76 ± 11 77 ± 8 
             +            ** 
 No AF 57 ± 10 84± 11 83 ± 10 86 ± 8 
Control group AF 58 ± 9 81 ± 13 84 ± 5 85 ± 11 
      
 No AF 56 ± 8 87 ± 12 87 ± 11 
**
85 ± 8 
*
Data are mean ± standard deviation. 
AF = atrial fibrillation. 
+  p <0.1*  p <0.05; **  p<0.01 between the groups. 
By multivariate analysis, the serum Mg2+ concentration (improvement in log-likelihood 7.1; p = 
0.008) and the sinus rate (improvement in log-likelihood 5.0; p = 0.025) were the only independent 
factors to predict the occurrence of AF among the patients who received Mg2+ by infusion. 
6.2.2. Ventricular arrhythmias 
There was a difference in the incidence of ventricular arrhythmias on the third postoperative day. In 
detail, the control patients had 12 ± 21 PVBs/h versus 4 ± 5 PVBs/h in the magnesium patients (p 
<0.05). The modified Lown classification showed a tendency toward a greater incidence of severe 
arrhythmias in the control group (p = 0.10; Figure 4). The incidence of complex ventricular 
arrhythmias was reduced in the patients on magnesium treatment (p <0.05; Figure 5). Sustained VT 
or VF did not occur. 
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Table 7. Ventricular arrhythmias in acute myocardial infarction.
 First 24 h  At discharge 
 Magnesium 
(n = 30) 
Control 
( n= 24) 
 Magnesium 
(n = 26) 
Control 
(n = 18) 
      
Mean sinus rate (beats/min) 72 (57 – 97) 70 (50 – 97)  66 (58 – 87) 68 (49 – 79) 
VPBs/h 6 (0 – 115) 29 (1 – 469)***  0 (0 – 6) 1 (0 – 130)* 
Number of couplet VPBs 3 (0 – 163) 13 (0 – 528)*  0 (0 – 2) 0 (0 – 16) 
Number of R-on-T VPBs 0 (0 – 4) 1 (0 – 89)**  0 (0 – 15) 0 (0 – 7) 
Number of slow VTs 0 (0 – 86) 4 ( 0 – 664)*  0 (0 – 0) 0 (0 – 1) 
Number of VTs 1 (0 – 38) 5 (0 – 248)*  0 (0 – 1) 0 (0 – 0) 
Values are median (range) . 
VPB = ventricular premature beat; R-onT = ventricular premature beats appearing on the T wave;  
VT = ventricular tachycardia. 
*  p <0.05; **  p <0.01; ***  p <0.001 between the groups.
6.3.2. Effect on determinants of ventricular arrhythmicity  
Autonomic regulation of the heart. In heart rate variability measurements, SDANN or the LF/HF 
ratio did not differ between the groups in either recording. The HF amplitude was lower in the 
patients in the magnesium group (Table 8). The BRS index could be determined in 34 patients (20 
of the magnesium-treated patients and 14 of the controls) and it was 6.6 ms/mmHg (1.0 - 14.6 
ms/mmHg) in the magnesium-treated group and 4.0 ms/mmHg (2.0 - 22.0 ms/mmHg) in the 
controls (NS).
Electrocardiographic repolarization. Table 9 summarizes the electrocardiographic data. The 
sinus cycle length, QT duration, QTc duration, PQ interval and QRS duration (figures not shown) 
did not differ at any measurement point between the groups. QTcD was significantly lower in the 
magnesium-treated patients throughout the study period. Although QTcD seemed to increase 
(though not statistically) during evolving AMI in the controls, it decreased among the patients who 
had received Mg2+ (p <0.05). At 24 h, QTcD values ≥ 100 ms (n = 12) occurred only in the control 
group (p <0.001). 
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Ischemia and size of acute myocardial infarction. By VCG, 18 (58 %) of the magnesium-
treated patients and 10/23 (43 %) of the controls had at least one episode of ischemia (NS). The 
number of episodes in these patients were 2 (1 - 13) and 3 (1 - 12), respectively (NS).  
During the first 24 h on Holter, 6 (19 %) of the magnesium-treated patients and 2 (8 %) of the 
controls had 17 (2 - 32) and 7 (3 - 11) episodes of ischemia, respectively (NS). At discharge, the 
corresponding incidences were 3/18 (17 %) and 2/12 (17 %) and the number of episodes 24 (4 - 37) 
and 18 (9 - 27), respectively (NS).  
Peak CK-MB release or the occurrence of ischemia in an exercise test did not differ between the 
groups. An emergency coronary angiography was performed in 7 (23 %) of the patients treated with 
Mg2+ and in 2 (8 %) of the controls (NS). Of these, 6 in the former and all in the latter led to 
percutaneous coronary intervention or CABG later during the hospitalization. 
By echocardiography, the left ventricular end diastolic diameter was 52 mm (39 - 59 mm) in the 
magnesium-treated patients and 54 mm (44 - 71 mm) in the controls (NS). The left ventricular EF did 
not differ between the groups: 57 % (23 - 76 %) in the former and 53 % (27 - 76 %) in the latter 
(NS). A positive late potential was detected in 7/28 (25 %) of the patients on Mg2+ treatment and in 
6/20 (30 %) of the controls (NS).  
Left ventricular failure identified radiologically developed in 7 (23 %) and in 6 (23 %) of the 
patients, respectively (NS). 
6.3.3. Associates of ventricular arrhythmicity  
There was an association between the appearance of ventricular arrhythmias during the first 24 h and 
serum Mg2+ concentration, and QTcD: The serum Mg2+ concentration after the infusion correlated 
inversely with VPB/h (rs = –0.47; p <0.01), the number of couplet VPBs (rs = –0.29; p <0.05), and 
the number of VTs (rs = –0.26; p <0.05). QTcD at 24 h correlated with VPB/h (rs = 0.48; p <0.001) 
and the number of VTs (rs = 0.27; p <0.05). The patients with QTcD ≥ 100 ms at 24 h had 
significantly more VTs (p <0.05) and VPB/h (p <0.01) during the first 24 h than those with QTcD < 
100 ms. There was no correlation between the incidence of ventricular arrhythmias and any of the 
HRV parameters, transient ischemia on VCG, or early use of intravenous -blockers.  
6.3.4. Other associates  
The serum Mg2+ concentration after the infusion correlated inversely with QTcD at 24 h (rs = –0.75; p 
<0.001) (Figure 6). There was also a negative correlation between the serum Mg2+ concentration and 
HF (rs = –0.45; p <0.01), but not between Mg2+ and the LF/HF ratio or SDANN during the first 24 h. 
In the patients with transient ischemia according to VCG (n = 28) or Holter (n = 8) during the first 24 
h QTcD did not differ from the patients free of ischemia.  
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Table 10. Changes in monophasic action potential duration during atrial pacing in individual patients.
 Baseline  Magnesium 
Patient MAPD50600 MAPD90600  MAPD50600 MAPD90600
      
VN 264 ± 1 300 ± 1  248 ± 0 272 ± 2 
YH 261 ± 2 293 ± 4  228 ± 3 249 ± 1 
SH 202 ± 4 236 ± 2  195 ± 4 226 ± 3 
TV 249 ± 0 277 ± 1  248 ± 5 279 ± 5 
HH-V 260 ± 3 296 ± 4  262 ± 2 298 ± 2 
AL 214 ± 2 267 ± 3  199 ± 1 258 ± 4 
RK 170 ± 1 237 ± 3  166 ± 2 210 ± 3 
PM 236 ± 1 312 ± 4  232 ± 0 305 ± 4 
IS 220 ± 1 269 ± 3  210 ± 2 266 ± 3 
AP 211 ± 3 258 ± 4  199 ± 2 245 ± 3 
PA 224 ± 2 256 ± 2  214 ± 3 238 ± 3 
TT 249 ± 2 292 ± 2  248 ± 0 288 ± 3 
Combined 230 ± 28 274 ± 25  221 ± 28** 261 ± 29 ** 
Data are expressed as mean ± standard deviation. 
MAPD50600, MAPD90600 = monophasic action potential duration at 50 % and 90 % repolarization 
during atrial pacing at a cycle length of 600 ms. 
**  p <0.01 between the baseline and magnesium phases. 
6.4.2. Ventricular refractoriness and other parameters 
Magnesium infusion shortened VERP at fixed cycle length from 247 ± 25 to 241 ± 21 ms (p <0.05), 
and the sinus cycle length from 783 ± 153 to 742 ± 160 ms (p <0.01). The QRS duration and the QT 
interval remained unchanged. There was a tendency toward a rise in systolic blood pressure (from 
139 ± 13 to 147 ± 15 mmHg; p = 0.06) in sinus rhythm, but not during atrial pacing. Diastolic blood 
pressure did not change. 
The pacing interventions had no effect on the sinus cycle length between the start and immediately 
after the VERP measurement at baseline (783 ± 153 ms versus 784 ± 154 ms, NS) or during the Mg2+
infusion (742 ± 160 versus 767 ± 149 ms, NS). The change in the spontaneous sinus cycle length (the 
baseline minus the maintenance infusion value) correlated with the changes in MAPD50 and MAPD90
(r = 0.58, p <0.05; and r = 0.55, p = 0.062, respectively), but not with the changes in MAPD50600, 
MAPD90600 or VERP.
67
6.5. Effect on intracellular magnesium and potassium concentrations 
In study V, there was a tendency toward an increase in the intracellular levels of both Mg2+ and K+
concentrations following the Mg2+ infusion (Table 11). The serum and intracellular concentrations of 
Mg2+ did not correlate, and the same was true for K+. Likewise, the concentrations of Mg2+ in the 
mononuclear cells and muscle tissue were not associated, so was the case for K+.
Magnesium-potassium relationship. There was a close correlation between the intracellular 
levels of Mg2+ and K+. This correlation was significant in mononuclear cells both at baseline (r = 
0.81; p <0.01 per protein and r = 0.96; p <0.001 per cell) and after the infusion (r = 0.85; p <0.01 per 
protein and r = 0.85; p <0.01 per cell). In muscle tissue, the association was significant at baseline (r 
= 0.83; p <0.01 per protein and r = 0.69; p <0.05 per wet weight) but not after the Mg2+ infusion.
The changes (post-infusion values minus baseline values) of the concentrations of Mg2+ and K+
correlated significantly both in mononuclear cells (r = 0.83; p <0.01 per protein and r = 0.61; p = 0.06 
per cell) and in muscle tissue (r = 0.79; p <0.01 per protein and r = 0.70; p <0.05 per wet weight). 
However, there was no correlation in the change of Mg2+ between mononuclear cells and muscle 
tissue and the same was the case for K+.
Table 11. Intracellular Mg2+ and K+ concentrations.
 Baseline 
(n = 11) 
Magnesium 
(n = 11) 
   
Mononuclear cell Mg2+   
     (nmol/mg prot) 41.8 ± 7.0 49.9 ± 19.3 + 
     (fmol/cell) 4.0 ± 1.4 4.7 ± 2.7 
Mononuclear cell K+   
     (nmol/mg prot) 436.3 ± 59.9 488.0 ± 123.3 
     (fmol/cell) 40.2 ± 11.4 46.4 ± 23.0 
Muscle tissue Mg2+   
     (nmol/mg prot) 72.4 ± 10.2 79.0 ± 7.5 + 
     (mmol/kg ww) 8.2 ± 1.2 8.6 ± 1.3 
Muscle tissue K+   
     (nmol/mg prot) 752.1 ± 141.0 792.5 ± 77.8 
     (mmol/kg ww) 83.9 ± 10.2 86.7 ± 13.4 
Data are expressed as mean ± standard deviation. 
ww = wet weight. 
+  p <0.1 between the phases. 
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7. DISCUSSION 
The main findings regarding the primary hypotheses were:  
1. The fall in the serum concentration of Mg 2+ following CABG was not unambiguously a cause 
of postoperative AF. A correction of this decline did not reduce the incidence of postoperative AF 
(Study I). 
2. The fall in the serum Mg2+ concentration following CABG was an independent predictor of 
postoperative ventricular arrhythmias, the occurrence of which could be reduced by correction of the 
decline (Study II). 
3. In the early phase of AMI, treatment with pharmacological doses of Mg 2+ suppressed
ventricular arrhythmias. The treatment led to improvement in the homogeneity of ventricular 
repolarization as determined by decreased QT dispersion. Magnesium had no effect on autonomic 
nervous balance, ischemia, or the extent of myocardial damage (Study III). 
4. A rapid infusion of a pharmacological dose of Mg 2+ shortened right ventricular MAP duration 
and refractoriness acutely in humans (Study IV).  
5. A close relationship between the intracellular handling of Mg2+ and K+ was demonstrated in 
patients with cardiac disease who were hospitalized for severe arrhythmias. The intracellular changes 
of these electrolytes could be monitored qualitatively both in blood mononuclear cells and skeletal 
muscle tissue (Study V).  
Secondary findings from the data were: 
Raising the serum Mg2+ concentration to a supraphysiological level following CABG may 
promote the generation of postoperative AF (Study I). 
There may be a pathophysiological link between elevated serum Mg 2+, decreased QT dispersion 
and decreased incidence of ventricular arrhythmias in the early phase of AMI, since these factors are 
interrelated (Study III).  
Magnesium administration does not change the electrocardiographic QT duration, whether under 
controlled state or altered by coronary artery disease (Studies III and IV).  
It is not possible to extrapolate the intracellular Mg2+ content by the serum concentration of Mg2+
(Study V). 
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7.1. Postoperative hypomagnesemia as an arrhythmogenic factor 
The postoperative decline of the serum Mg2+ concentration (and hypomagnesemia) did not 
predispose to AF but was a contributor to the genesis of ventricular arrhythmias. Postoperative 
hypomagnesemia and low serum Mg2+ levels have previously been associated with AF 
(supraventricular arrhythmias) but the association has not been uniform. Two studies have clearly 
demonstrated an increased incidence of AF in hypomagnesemic patients (England et al. 1992, Zaman 
et al. 1997). Multivariate analysis, not commonly performed in these studies, showed low serum 
Mg2+ concentration on the first postoperative day as a factor with independent, albeit low positive 
predictive power, in estimating the risk of postoperative AF (Zaman et al. 1997). Combined with an 
increased P wave duration in signal averaged ECG, hypomagnesemia could more reliably identify the 
patients on risk of future AF (Zaman et al. 1997). In contrast to these two reports, there are large 
studies with the intent to reveal risk factors of postoperative atrial arrhythmias and these have not 
raised hypomagnesemia as a risk factor (Creswell et al. 1993, Aranki et al. 1996, Mathew et al. 
1996). While the role of hypomagnesemia as an independent generator of postoperative AF remains 
uncertain, the results of Zaman and coworkers (1997), could, at best, be interpreted so that in the 
presence of an adequate substrate, Mg2+ could act as a modulator in the provocation of the 
arrhythmia. A true lack of hypomagnesemia in the present series does not allow evaluation of the 
contribution of hypomagnesemia to the incidence of postoperative atrial arrhythmias. 
Hypomagnesemia or decreased serum level of Mg2+ has not been included as an established risk 
factors for postoperative ventricular arrhythmias. A low serum Mg2+ level in the present series was 
an independent predictor of high-risk ventricular arrhythmias, and as the study period was confined 
to the precise decline in the serum Mg2+ concentration, a close association can be suggested. 
However, the rare occurrence of hypomagnesemia and the study approach itself cause uncertainty in 
making definitive conclusions about the role of hypomagnesemia as an arrhythmogenic factor. 
7.2. Magnesium administration and postoperative atrial fibrillation 
The present data indicate that correction of the postoperative decline in the serum Mg2+ level did not 
reduce the incidence or recurrence of AF, nor did it postpone the appearance of AF. The response to 
Mg2+ administration with regard to postoperative atrial arrhythmias (mainly AF) has been variable. In 
placebo-controlled studies, Mg2+ has reduced the incidence of postoperative AF episodes by 50 – 71 
% (Fanning et al. 1991, Colquhun et al. 1993). In the study by Fanning and coworkers (1991), a high 
dose of Mg2+ was used, producing a 2-fold increase in the postoperative serum Mg2+ concentration. 
In the study by Colquhun et al. (1993), the Mg2+ dose and the achieved serum concentration were 
close to our protocol. Wistbacka and coworkers (1995) compared two different dosing schedules 
(high dose and low dose) and demonstrated that doubling the physiological Mg2+ level was needed to 
lower the AF incidence. In conclusion, data from the prevailing literature suggest that a decrease in 
the occurrence of AF after CABG has been gained by large Mg2+ doses and by reaching a 1.5 - 2-fold 
increase in its serum concentration. The postoperative nadir of the Mg2+ concentration does not 
determine the effect and, thus, a true pharmacological action rather than correction of a magnesium 
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deficit probably explains the results. 
In the present data, patients with very high serum Mg2+ concentrations had more frequently 
postoperative AF than normomagnesemic patients. This contradicts the above mentioned results. 
While a primary proarrhythmic effect of hypermagnesemia seems unlikely in the light of literature, 
the possibility of proarrhythmia secondary to the intervention must be considered. Our treatment 
groups differed postoperatively with respect to three variables: serum K+ and Ca2+ concentrations
(Table 12) and sinus heart rates. The K+ concentration in the group of patients who received Mg2+
was higher than among the controls on the third day. This change, which did remain within the 
reference range, is just enough to oppose the condition that favors arrhythmias, and is probably of no 
relevance. The serum Ca2+ concentration was lower in the magnesium-treated group, but by 
multivariate analysis it was not of predictive value. The hypocalcemic values recorded in both groups
probably reflect postoperative hypoalbuminemia secondary to postperfusion hemodilution; ionized 
Ca2+ was not measured. 
Table 12. Postoperative serum electrolyte changes.
   Postoperative day  
  0 1 3 5 
      
Serum Mg2+ (mmol/l) Magnesium 0.83 ± 0.07 1.09 ± 0.17 0.88 ± 0.17 0.81 ± 0.08 
                 ***               ***                     
 Control 0.84 ± 0.08 0.77 ± 0.10 0.77 ± 0.09 0.83 ± 0.10 
      
Serum K+ (mmol/l) Magnesium 4.14 ± 0.27 4.56 ± 0.33 4.26 ± 0.27 4.26 ± 0.32 
                                        ***                        
 Control 4.11 ± 0.32 4.62 ± 0.47 4.06 ± 0.26 4.21 ± 0.41 
      
Serum Ca2+ (mmol/l) Magnesium 2.37 ± 0.09 1.85 ± 0.14 1.98 ± 0.11 2.12 ± 0.11 
                     *   
 Control 2.35 ± 0.09 1.90 ± 0.11 2.01 ± 0.08 2.09 ± 0.11 
Values are mean ± standard deviation. 
*  p <0.05; ***  p <0.001 between the treatment groups. 
An important observation that may be made from this study was that supraphysiological Mg2+
levels after CABG decelerate the sinus heart rate, which may partially explain why AF was generated 
in the present series. Regarding only those AF patients whose arrhythmia occurred on the first three 
days, their sinus rates were significantly slower on each day (Table 5). This suggests that the 
deceleration was an actual treatment effect. Why Mg2+ administration causes the sinus rate to 
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decrease can only deductively be estimated from the present data. Slowing of the sinus rate mimics 
the effect of enhanced parasympathetic action, which is known to predispose to AF through 
shortening of the atrial refractoriness (Allessie et al. 1990). Experimental studies have shown that 
Mg2+ can reduce the sinus rate and increase the sensitivity of the cardiac pacemaker cells and AV 
conductive system to the inhibitory effect of acetylcholine (Toda and West 1967, Somjen and 
Baskerville 1968). Magnesium can also reduce the excretion of catecholamines from nerve endings 
by attenuating their release and by facilitating their uptake (von Euler and Lishajko 1973). Thus, high 
serum Mg2+ concentrations were likely to inhibit the postoperative rise in the sinus heart rate and 
provoke AF by interacting with the autonomic regulation mechanisms of the cardiac rhythm. 
7.3. Magnesium administration and postoperative ventricular arrhythmias 
The present data allude that ventricular arrhythmias arising concomitantly with the decline in the 
postoperative serum Mg2+ concentration are suppressed by magnesium. This finding corresponds 
with the results of some previous studies, but not all. The dose and the postoperative serum Mg2+
level after treatment seem to be of minor importance.  
The study approach offers only circumstantial evidence about the mechanisms of the action of 
magnesium. The electrical instability after cardiac surgery might be derived from pre-existing 
structural arrhythmia substrate, ischemia and perioperative myocardial infarction, catecholamine 
stimulation, reperfusion, and postoperative electrolyte dysequilibrium. Ischemia relief, supported by 
a slight tendency toward a smaller perioperative myocardial infarction incidence in the magnesium-
treated group (13 % vs 24 %; p = 0.13), could account for the effect. Although suppression of 
reperfusion-induced ventricular arrhythmias by Mg2+ has been reported (Komori et al. 1999) the 
explanation remains questionable here because the beneficial effect of magnesium is only 
documented when administered before reperfusion, and in Study II it was started after chest closure 
(Christensen et al. 1995, Herzog et al. 1995).  
Lowered myocardial Mg2+ concentrations have been reported in patients with arrhythmias after 
cardiac surgery (Reinhart et al. 1991). Given the slow cellular exchange of Mg2+ and the present 
observation that the advantageous effect was more obvious on the third than on the second 
postoperative day, repletion of myocardial Mg2+ deficiency might explain the protracted favorable 
effect (Polimeni and Page 1973, Reinhart 1988).  
Long-term diuretic therapy promotes the development of ventricular arrhythmias by inducing 
hypokalemia and K+ depletion (Stewart et al. 1985, Gettes 1992). The close relationship in the 
metabolism and cellular actions between Mg2+ and K+ explains the coexistent depletion of these 
cations in patients with ischemic heart disease on diuretics (Watanabe and Dreifus 1972, Dyckner 
and Wester 1979, Reinhart 1988, Gettes 1992). Thus, it is understandable that the use of diuretic 
treatment preoperatively is related the development of ventricular arrhythmias and also that the 
occurrence of these arrhythmias is alleviated by magnesium therapy.  
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7.4. Magnesium and ventricular arrhythmias in acute myocardial infarction 
The reduction in the occurrence of ventricular arrhythmias in the present study was substantial during 
the Mg2+ magnesium infusion, suggesting a true treatment effect. In other studies evaluating the first 
24 h effect, Abraham and coworkers (1987) showed a reduction in the incidence of ventricular 
arrhythmias from 34.8 % to 14.6 %, and Ceremuski and coworkers (1989) from 78 % to 28 %. 
The LIMIT-2 study reported no suppression of clinically documented peri-infarct arrhythmias, as did 
not a Holter substudy of 48 patients (Woods et al. 1992, Roffe et al. 1994). Thögersen and coworkers 
(1995) found only a tendency toward a reduction in the number of episodes of repetitive VPBs. In 
studies with a longer follow up, the degree of reduction of arrhythmias has been variable. In ISIS-4, 
the largest trial assessing the effect of magnesium in AMI, fewer patients with magnesium treatment 
experienced VF during hospitalization than patients who did not receive magnesium, without 
consequent implications on overall mortality (ISIS-4 Collaborative Group 1995). Combining the 
heterogenous arrhythmia definitions, registration periods, and administration protocols, the meta-
analysis of small-scale trials, most of which were conducted without fibrinolytic treatment, revealed a 
49 % reduction in the incidence of VT and VF by Mg2+ treatment (Horner 1992). Magnesium dosing 
in Study IV corresponds with the one in LIMIT-2 and, yet, the responses were different. A higher 
proportion of patients treated with fibrinolytics (~90 % versus ~36 %) and the later start of 
magnesium administration in Study IV might contribute to the difference.  
7.5. Magnesium and determinants of ventricular arrhythmias in acute myocardial 
infarction 
Inhomogeneity in repolarization. The data in Study IV demonstrate that the early increase in QT 
dispersion, known to follow AMI (Mirvis 1985, Higham et al. 1995), is abolished by magnesium 
treatment and the effect is maintained for up to one week. The response is not attributed to alterations 
in QT or QTc durations, which remained comparable between the treatment groups. This is in 
agreement with previous findings that QT dispersion is not related to QT duration directly, and 
interventions that prolong QT duration do not implicitly increase QT dispersion (Cui et al. 1994). 
Furthermore, magnesium administration does not alter the electrocardiographic QT interval in 
healthy subjects either (DiCarlo et al. 1986).  
It is well recognized that ongoing ischemia and its consequences, alterations in the nervous 
regulation of the heart, and pharmacochemical interventions can modify repolarization. In Study IV, 
transient ischemia, peak CK-MB release, and HRV measures were not associated with the degree of 
QT dispersion. In contrast, serum Mg2+ level was and this suggests that Mg2+ might be a potent 
determinant in the homogenization of repolarization.  
The difference in the QTD was still discernible at one week, implying that magnesium treatment 
might have induced long-term modifications in the evolving arrhythmia substrate. Since long-term 
influences were beyond the scope of this study, the issue cannot be confirmed by exploration of later 
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occurrence of life-threatening ventricular arrhythmias or sudden death, the definitive representatives 
of unstable chronic arrhythmia substrates.  
Autonomic control of the heart. Magnesium exerted no influence on the sympathovagal balance 
either in the early phase or at discharge, as demonstrated by unchanged SDANN or LF/HF ratio. The 
early decrease in the HF amplitude in the magnesium-treated patients probably reflects the anterior 
AMI dominance in these patients, since anterior AMIs were associated with a lower HF amplitude, 
which has been reported by other groups as well (Singh et al. 1996, Lombardi et al. 1996). 
Furthermore, BRS was not influenced by magnesium treatment. It has been shown that impairment of 
cardiac neural function occurs within minutes after cessation of coronary blood flow and rapid 
interventions are expected to achieve reversibility (Zipes 1991). Relatively late administration of 
magnesium after the onset of symptoms and fibrinolytic treatment may have failed to save the 
function of autonomic innervation within the myocardium. Given the fact that magnesium can 
produce both sympatholythic and anticholinergic responses the neutral effect on the autonomic 
reflexes is understood (Somjen and Baskerville 1968, von Euler and Lishajko 1973). 
Ischemia and acute myocardial infarction size. Although experimental data favor the anti-
ischemic (Altura et al. 1987, White and Hartzell 1989, Vigorito et al. 1991) and reperfusion injury 
reducing (Herzog et al. 1995, Christensen et al. 1995) properties of Mg2+, early ischemia suppression 
by Mg2+ could not be verified in Study IV. Despite the fact that Mg2+ reduces ischemia in patients 
with unstable angina (Redwood et al. 1997), it obviously cannot restrict early residual ischemia once 
infarction has ensued (ISIS-4; our data). Furthermore, the extent of myocardial damage, assessed by 
cardiac enzyme release, left ventricular dimensions and function, or appearance of late potentials, 
were not affected. This is consistent with in vivo studies showing infarct size limitation only if 
magnesium administration is initiated before or at the time of reperfusion (Herzog et al. 1995, 
Christensen et al. 1995). 
Determinants of arrhythmia suppression. Based on the close relationship between serum Mg2+
levels, QT dispersion and attenuation of early ventricular arrhythmias, the diminished arrhythmicity 
may be attributed to the ability of Mg2+ to decrease the repolarization abnormality reflected in QT 
dispersion. In general, while QT dispersion identifies patients at increased risk for arrhythmic death, 
an association between decreased QT dispersion and suppression of ventricular arrhythmias has not 
been confirmed in AMI patients previously.  
The ability of magnesium to modify repolarization has been demonstrated in both experimental 
and clinical ischemia (Kraft et al. 1980, White and Hartzell 1989, Redwood et al. 1996). Whether the 
consequent arrhythmia suppression is attributed to a primary ischemia relief or restoration of the 
ischemia-induced derangement of the electrochemical gradient across the sarcolemma is not known. 
Based on the present clinical data, it may be assumed that the principal action of Mg2+ is to modify 
the unstable electrical environment, not to alleviate ischemia. This gains support from the observation 
that Mg2+ acted electrically, i.e., prevented arrhythmias, and not by reducing ischemia or infarction. 
Secondly, dispersion of the repolarization reflects conditions in the electrophysiological substrate for 
ventricular arrhythmias (Schneider et al. 1997). Thirdly, given the dependence of QT dispersion on 
the location (present study) and the extent of infarction (Moreno et al. 1994), magnesium's influence 
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was independent of them.  
7.6. Magnesium and ventricular electrophysiology 
Action potential duration. In Study III, Mg2+ caused an acute shortening of MAP duration during 
sinus rhythm and at a controlled heart rate. A shortening of the monophasic or transmembrane action 
potential in ventricular muscle after magnesium administration is not an established response. 
Watanabe and Dreifus (1972) demonstrated prolongation of transmembrane action potential duration 
by high and shortening by low extracellular Mg2+ levels. The effect was clearly related to the 
extracellular K+ concentration. Surawicz and coworkers (1961) found no change in MAP duration. It 
was shortened, however, if the extracellular Ca2+ concentration was lowered. These responses could 
be detected at a very high perfusate Mg2+ concentration only, and such concentrations cannot readily 
be reached in clinical therapeutic situations.  
The effect of Mg2+ is more evident if the action potential is modified pharmacologically or by a 
disease. Thus, Mg2+ shortens the action potential of isolated canine Purkinje fibers prolonged by 
quinidine (Davidenko et al. 1989). In ischemia, the very early MAP prolongation is eliminated 
(Redwood et al. 1996), and later shortening is reversed by Mg2+ (Kraft et al. 1980). In cardiac 
transplant patients, Mg2+ tends to prolong MAP duration (Millane et al. 1992). In the transplanted 
heart, as in isolated heart models, autonomic innervation is largely eliminated and, hence, they 
represent an altered physiological condition. 
Refractoriness. Data from Study III add to prior findings concerning the effect of Mg2+ on 
ventricular refractoriness. Studies in patients with and without organic heart disease using 
comparable stimulation techniques and magnesium dosage have not demonstrated a change in VERP 
(DiCarlo et al. 1986, Kulick et al. 1988). The difference between the present and the previous 
observations is possibly explained by the time factor: in the present study rapid responses were 
measured, which have been overlooked in steady state studies. Whether Mg2+ alters ventricular 
refractoriness only acutely remains to be elucidated. 
Mechanisms of the observed changes. Experimental evidence supports the concept that Mg2+
can affect the action potential duration and consequently refractoriness. While the responses have 
been observed in situations where repolarization is disturbed, the subjects in Study III were 
practically devoid of such morbidity. The increase in the heart rate after Mg2+ administration 
indicates that the MAP and VERP alterations simply followed the changes in sinus cycle length since 
monophasic and transmembrane action potential durations depend strongly on cardiac cycle length 
(Boyett and Jewell 1980). Furthermore, the finding that the magnitudes of the changes in sinus cycle 
length and MAP duration correlated suggests that the effect during spontaneous rhythm could, at 
least partly, be associated with mechanisms that also influence heart rate. However, the shortenings 
of the MAP duration and VERP, when the heart rate was controlled by pacing, indicates that the 
shortenings were not due to heart rate change exclusively.  
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The causes of heart rate increase are not evident: magnesium has a neutral or slightly depressant, 
but not a direct accelerating effect on the sinus node (DiCarlo et al. 1986, Kulick et al. 1988). The 
sinus cycle length shortening could be secondary to the vasodilative properties of Mg2+ and the 
consequent activation of baroreceptors (Vigorito et al. 1991). Blood pressure did not change, and 
therefore a reflex increase in heart rate to compensate for hypotension is unlikely. The possibility of 
experiment-produced stress to provoke catecholamine secretion, suggested by the tendency of the 
systolic blood pressure to rise even at constant rate, cannot be ignored since plasma catecholamine 
levels were not measured.  
Modulation of the autonomic regulation of the heart by Mg2+ might explain the findings in Study 
III. Magnesium reduces the negative chronotropic response to vagal stimulation of isolated rabbit 
atria, probably by decreasing the release of acetylcholine (Toda and West 1967, Somjen and 
Baskerville 1968). Magnesium may thus have acted as an anticholinergic agent. Autonomic blockade 
was not used and therefore the possibility of autonomic modulation can not be excluded.   
Ventricular pacing may reduce blood pressure, and through consequent sympathetic activation or 
vagal withdrawal increase the heart rate and shorten the MAP duration and refractoriness. This 
possibility seems unlikely since sinus cycle length did not change when compared between the start 
and the end of the test neither at baseline nor during the Mg2+ infusion and, thus, the shortenings 
should not be a consequence of the stimulation procedure itself.  
7.7. Intracellular magnesium 
The baseline mononuclear cell and muscle tissue levels of Mg2+ and K+ in the present study are on 
average 25 % below the levels reported previously in healthy persons, and comparable with most 
investigations in similar settings (Elin and Johnson 1982, Elin and Hosseini 1985, Ryzen et al. 1986, 
Sjögren et al. 1987, Dørup et al. 1988, Ralston et al. 1989). The Mg2+ /K+ ratio in the present study 
was approximately 1:10 in the both cell types, and regardless of analytical variations it is concordant 
with prior data obtained among healthy persons, patients with ischemic heart disease and patients on 
diuretic therapy (Dyckner and Wester 1979, Abraham et al. 1985, Abraham et al. 1986, Dørup et al. 
1988).  Furthermore, the provoking role of diuretics to induce intracellular electrolyte depletion 
(Reinhart 1988, Dyckner and Wester 1987c, Ryan et al. 1981) was mirrored as a tendency for lower 
K2+ and Mg2+ levels (Ralston et al. 1989).
Correlation between different cell types. The results of Study V are in concordance with 
previous observations that the serum Mg2+ concentration correlates poorly with its intracellular 
levels, including myocardial cells (Reinhart 1988, Ralston et al. 1989). Likewise, the correlation has 
been weak between skeletal and cardiac muscle and mononuclear cells in patients (Reinhart 1988, 
Ralston et al. 1989, Baldwin et al. 1952) but suggested to be stronger in healthy subjects (Sjögren et 
al. 1987, Dyckner and Wester 1985). Adding to the prevailing knowledge, a change in the 
intracellular level of Mg2+ following the infusion did not correlate between the different cell types in 
the present study.  
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Different cell kinetics and transmembrane exchange capabilities, and timing of blood and skeletal 
muscle sampling may account for the weak correlation between the cell specimens. Rapidity and 
linearity of the changes remain open, since for ethical considerations serial muscle sampling could 
not be done. It is possible that the uptake of Mg2+ may be slower in skeletal muscle than in 
mononuclear cells, since mononuclear cells are readily accessible to intravenously administered Mg2+
and liable to more rapid changes than skeletal muscle tissue. The effect of the Mg2+ infusion on the 
extracellular fluid of skeletal muscle is delayed but obviously more stable, possibly reflecting the 
overall body Mg2+ status more reliably. Factors affecting cellular electrolyte kinetics are 
incompletely known but it has been suggested that the lifespan of mononuclear cells may be 
shortened in patients with various underlying heart diseases (Dyckner and Wester 1985). Moreover, 
medications and catecholamine release may alter the cell membrane transport and permeability of 
Mg2+ differently (Romani and Scarpa 1990). 
Magnesium-potassium relationship. A close connection between intracellular Mg2+ and K+ has 
been documented among healthy persons and in patients (Baldwin et al. 1952, Abraham et al. 1986, 
Whang 1986, Ralston et al. 1989). The results of Study V show the dynamics of this interrelationship 
as a direct correlation between the changes in Mg2+ and K+ following the infusion in the both tissue 
types. While this has been proposed to be attributed to diuretic use (Dyckner and Wester 1979), the 
present data suggest that the phenomenon is unrelated to it.  
The intimate coupling of Mg2+ and K+ implicates the coexistence of intracellular depletion of the 
two cations and vice versa, a prerequisite for normalization of reduced intracellular K+ content is 
restoration of Mg2+ status (Whang and Welt 1963). The promoting role of pre-existent cellular Mg2+
deficiency as a catalyst for K+ depletion is demonstrated in the present study: the lower the baseline 
intracellular Mg2+ concentration was, the higher the intracellular K+ gain became (Figure 7). This 
action can be ascribed to the regulatory function of Mg2+ on the membrane bound Na+-K+ pump, 
whose activity is controlled linearly by intracellular free Mg2+ (Polimeni and Page 1973, Flatman and 
Lew 1981). Furthermore, the activity of this ion pump is suppressed in patients with decreased EF 
(Norgaard and Kjeldsen 1989). In agreement with the results of Study V, Haigney and coworkers 
(1997) reported reduced tissue Mg2+ concentrations in patients with a low EF and ventricular 
arrhythmias. Current data also imply that the link between Mg2+ and K+ may not be operative at the 
kidney level, because the interaction could also be seen in patients whose electrolyte excretion 
through the kidneys had not been modified by diuretic therapy.  
7.8. Methodological considerations 
General. The incidence of postoperative atrial arrhythmias (AF) in Study I, 29 % in the magnesium 
patients and 26 % in the controls, fits with the range reported previously (Lauer et al. 1989, Rubin et 
al.1987, Andrews et al. 1991). The incidence does, however, exceed slightly the frequency reported 
in another study (15.3 %) where systematic metoprolol treatment was also given (Jansen et al. 1986). 
While the incidence may depend on the technique used to disclose arrhythmias, Holter recording in 
our series did not increase the sensitivity of atrial arrhythmia recognition.  
78
The incidence of complex ventricular arrhythmias in the control group (41 %) in Study II is 
slightly higher than observed by Ferraris and coworkers (1991) who found that 23 % of patients 
developed serious postoperative ventricular arrhythmias. Their observation period consisted of the 
whole hospital stay and they utilized continuous electrocardiographic monitoring with arrhythmia 
detection circuits and visual inspections of the tracings. Furthermore, their criteria of serious 
ventricular arrhythmias correspond with the high-risk arrhythmias in Study II, which occurred in 18 
% of the patients on the two-day study period. The increased sensitivity of Holter monitoring to 
identify ventricular arrhythmias explains the rather high incidence of complex ventricular 
arrhythmias, which agrees with the 37 - 78 % incidence previously reported (Michelson et al. 1979, 
Rubin et al. 1985, Chiolero et al. 1991).
The postoperative decline in serum Mg2+ was clear in Study I. The decline persisted for three days 
and disappeared by the fifth day, and this finding is concordant with previous reports (Bunton 1983, 
England et al. 1992, Zaman et al. 1997). However, true hypomagnesemia (serum Mg2+ below the 
lower reference value) was detected among only 14 % of the patients on the first day and among 13 
% on the third day in the control group; these figures contradict the much higher percentage reported 
by others (England et al. 1992, Zaman et al. 1997). Catecholamine burst, known to lower the serum 
levels of Mg2+ (Flink et al. 1981), was minimized by systematic use of postoperative -blockers in 
Studies I and II. Furthermore, the constitution of the crystalloid solution used to prime the 
cardiopulmonary bypass pump, not reported in other studies, contained 16 mmol/l Mg2+ in Studies I 
and II.  
There was an unbalance in some variables between the treatment arms in the study of patients 
undergoing CABG (Studies I and II). Subjects belonging to the magnesium-treated group were 
slightly older, prior AF was more common among them, and consequently, their digitalis use was 
more frequent. Furthermore, in univariate analysis, those patients who experienced AF were older 
(59 ± 7 versus 55 ± 8 years; p <0.01) and more of them had had preoperative AF episodes (13 % 
versus 2 %; p <0.05). This unfortunate randomization bias, however, did not have impact on the main 
hypothesis of the study, since by multivariate analysis, only serum Mg2+ and sinus rate predicted the 
appearance of AF. Advanced age has been the most uniform risk factor found in a number of studies 
(Kannel et al. 1982, Lauer et al. 1989, Fuller et al. 1989, Leitch et al. 1990, Creswell et al. 1993, 
Zaman et al. 1997) and the results of Study I are consistent with these data. Prior AF is an expected, 
yet only incidentally recognized risk factor (Mathew et al. 1996), since AF predisposes to future 
appearance of AF through electrical remodelling of the atria (Wijffels et al. 1995). 
In the study of AMI (Study III), the distribution of anterior and inferior infarctions in the study 
groups was different. However, the effect of Mg2+ was independent of this. Thus, among the patients 
with an anterior or inferior Q wave AMI, QTcD throughout the study period and the incidences of 
ventricular arrhythmias were reduced in the magnesium-treated patients compared to the controls. 
Furthermore, HRV and ischemia did not differ. Overall, ventricular arrhythmias, QTD, QTcD, 
LF/HF ratio, and the indexes of ischemia were equally distributed in the patients with an anterior or 
an inferior AMI (figures not shown). However, the patients who had an anterior Q wave AMI had 
greater peak CK-MB levels (175 g/l (7 - 1106 g/l) vs 97 g/l (9 - 538 g/l); p <0.05), and lower 
SDANN (p <0.05) and a lower HF amplitude (p <0.01) on the first 24 h Holter recording than the 
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patients with an inferior AMI.  
MAP recording. Experimental studies have demonstrated that it takes 1 to 2 minutes for the 
ventricular action potential duration to reach steady state after a change in heart rate (Morady et al. 
1988). The atrial pacing for only a half minute preceding the MAP recording may have been too 
short, but short pacing allowed examination of the rapid effects of Mg2+. Although the pacing drive 
length was identical at baseline and during magnesium infusion, it may not have completely 
eliminated the influence of starting the train at dissimilar preceding heart rates. Likewise, also VERP 
is sensitive to the heart rate of the intertrain period (Morady et al. 1988).  
The effect of Mg2+ was tested at two cycle lengths only, i.e., spontaneous and 600 ms. Whether 
Mg2+ acts in use-dependent mode at shorter cycle lengths could not be established. 
QT dispersion. It is well known that it is not unproblematic to measure the QT interval from the 
standard 12-lead ECG, especially to define the end of the T-wave and to separate the U-wave from 
the T-wave (Kautzner and Malik 1997). Indeed, manual measurement techniques suffer from a 
substantially low reproducibility, with up to 35 % intra- and interobserver relative error when healthy 
subjects are assessed (Kautzner et al. 1994). The variability may be smaller in patients with AMI or 
in postmyocardial patients at risk for ventricular tachycardia (van de Loo et al. 1994, Perkiömäki et 
al. 1995), particularly if techniques based on automatic analysis algorithms are used (Oikarinen et al. 
1998). The reproducibility of the measurements during the early phase of AMI is unknown.  
Of the twelve standard ECG leads, only the precordial leads probably yield information about 
local myocardial recovery of excitability (Kors and van Herpen 1998). The ability of these leads to 
reflect spatial, transmural, or microlevel changes, probably most relevant in arrhythmia generation, 
has been questioned (Surawicz 1996). Yet, in ischemic heart disease, QT dispersion is recognized as 
a marker of regional inhomogeneity in ventricular refractoriness, a prerequisite for reentrant 
ventricular tachyarrhythmias (Janse and Witt 1989), because it has identified propensity to 
ventricular arrhythmias based on reentry. Accordingly, the reduction in QT dispersion in Study IV 
explains incompletely the decrease in the incidence of VPBs, which are considered to be an 
expression of increased excitability due to acute ischemia (Janse and Witt 1989). It was not possible 
to evaluate if true reentrant ventricular arrhythmias, sustained VTs, could be prevented by Mg2+.
Heart rate variability and baroreflex sensitivity. Although magnesium under experimental 
conditions alters sympathetic and parasympathetic cardiac responses, such an effect could not be 
demonstrated by HRV or BRS analysis in patients with AMI (Study IV). The linear time and 
frequency domain measures of HRV are sensitive to ectopic beats, which are common early after the 
onset of an  AMI. It may be argued that application of artificial correction techniques to compensate 
for rhythm irregularity ends in underestimation of the autonomic nervous status. Furthermore, these 
HRV methods reflect long-term fluctuations in the neural input to the heart. They are validated as 
prognostic markers, and not necessarily as specific triggers of acute arrhythmic events (Huikuri et al. 
1999). Whether novel methods based on nonlinear dynamics would have given better information 
about the effect of Mg2+ remains unknown. Furthermore, the power of BRS could only be evaluated 
in a subset of patients. 
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Vectorcardiography. VCG, like scalar ECG is sensitive to electric interference consequent to 
electrode displacement and changes in body position (Lundin et al. 1995). Hence, care was taken to 
inspect visually all changes indicative to ischemic episodes to exclude false-positive VCG changes. 
Heart rate, ventricular hypertrophy, and left ventricular chamber size can influence VCG parameters, 
but they were unlikely to bias the groups since cycle lengths and echocardiographic findings were 
comparable. Patients with bundle branch block, if defined as having myocardial infarction, were not 
excluded from the analysis, since VCG is more accurate than scalar ECG in diagnosing ischemia in 
AMI patients (Chou 1986). 
Intracellular magnesium measurement. The disparities in the intracellular levels of Mg2+
between previous studies and the present Study V may have multiple explanations. The intracellular 
analysis method used in this study complies with the mostly utilized techniques. However, the 
methods are not standardized with respect to cell separation and washing techniques. Separation and 
washing of the cells with buffered-saline glucose solution may cause leakage of Mg2+ from the cells 
due to transport of Mg2+ across the cell membrane and premature lysis of the cells. Some 
investigators have used leukocytes instead of mononuclear cells, which may have resulted in higher 
concentrations. Thus, the changes of Mg2+ and K+ should be seen as dynamic rather than absolute. 
7.9. Clinical implications 
It would be important to identify patients prone to postoperative arrhythmias for preventing the 
morbidity associated with arrhythmias. According to the present data, the inevitable postoperative 
decline in the serum Mg2+ level indicates an increased risk for ventricular arrhythmias but not for AF. 
From a therapeutic point of view, a vigorous correction of the decline with intravenous 
administration of Mg2+ is not warranted (Studies I, II) 
Shortening of the duration of MAP may provide relevance in treating arrhythmias evoked by 
action potential prolongation and disturbed repolarization, as in the acquired long QT syndrome and 
heart failure (Davidenko et al. 1989, Tomaselli et al. 1994). The present data suggest that 
administering magnesium rapidly leads to very acute changes in MAP duration and sinus cycle 
length, i.e., shortening of the action potential duration, that are traditionally reached for by pacing at a 
moderately high rate (Tzivoni et al. 1988, Davidenko et al. 1989). However, the observed effect on 
the MAP duration was quite subtle in these patients who did not have QT prolongation and the 
clinical implication of a change of this magnitude needs to be confirmed (Study III).  
Despite the early reduction in the occurrence of ventricular arrhythmias in AMI, this study lacked 
robust end-points (sustained VT, VF and arrhythmic death) and the nature of the study was 
mechanistic rather than prognostic. These circumstances do not allow an estimation of the clinical 
significance of the observed changes on morbidity and survival. However, an increased frequency of 
VPBs at discharge after AMI has predicted an adverse outcome also in the fibrinolytic era (Statters et 
al. 1996, Maggioni et al. 1993). Increased homogeneity in repolarization, which was now 
demonstrated to sustain through the recovery phase, may protect against the generation of life-
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threatening ventricular arrhythmias or sudden death. A variable influence of Mg2+ treatment on the 
prognostic markers may partly explain the discrepant outcomes in the studies evaluating the effect of 
Mg2+ on survival after AMI (Study IV). 
Previous experiments have suggested that mononuclear cell or skeletal muscle electrolyte changes 
could be extrapolated to myocardial cells. Given the observed dynamic coupling of intracellular Mg2+
and K+, a plausible explanation behind magnesium’s salutary effect on some cardiac arrhythmias 
would be restoration of the K+ status in cardiac cells (Study V). 
8. CONCLUSIONS 
Serum Mg2+ concentration falls significantly following CABG but it does not cause AF. 
Hypomagnesemia can be prevented by infusion of 70 mmol of MgSO4 during the first two 
postoperative days, but it does not decrease the incidence of AF. Instead, high levels of serum Mg2+
are likely to provoke AF by mechanisms that modify sinus rate (Study I). 
Correction of the postoperative decline in the serum Mg2+ levels decreases the incidence of VPBs 
and complex ventricular arrhythmias. The suppressive influence on high-risk ventricular arrhythmias 
is particularly accentuated in patients with advanced coronary artery disease treated with diuretics 
prior to the operation (Study II). 
It is possible to shorten the ventricular MAP duration and refractoriness by administering 
intravenous MgSO4 rapidly. The changes are moderate and may be partly mediated by mechanisms 
that also increase heart rate (Study III). 
Magnesium given intravenously in the early phase of AMI attenuates the incidence of ventricular 
arrhythmias. The reduced arrhythmicity is linked to preservation of homogeneity of repolarization, 
but not to improvement of autonomic regulation of the heart, alleviation of ischemia, or myocardial 
salvage (Study IV). 
In hospitalized patients with underlying heart disease and severe cardiac arrhythmias, the 
intracellular Mg2+ concentrations correlate closely with the intracellular K+ levels. Magnesium 
infusion causes predictable and parallel changes in the intracellular K+ concentrations, with inverse 
relationship between the baseline intracellular Mg2+ and the respective K+ gain. Myocardial function 
contributes to the associations (Study V). 
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